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The antimalarial MMV688533 provides single-dose cures with a high 1 
barrier to Plasmodium falciparum parasite resistance 2 
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One Sentence Summary: We report an acylguanidine preclinical candidate with efficacy, resistance 43 
and pharmacological features compatible with single low-dose malaria cure.   44 
 - 3 - 3 
ABSTRACT 45 
The emergence and spread of Plasmodium falciparum resistance to first line antimalarials creates an 46 
imperative to identify and develop novel potent chemotypes. Here we report the identification of 47 
MMV688533, an acylguanidine discovered using an orthology-based screen, which displays fast 48 
parasite clearance in vitro and is not cross-resistant with known antimalarials. In a P. falciparum 49 
SCID mouse model, MMV688533 displays a long-lasting pharmacokinetic profile and excellent 50 
safety. Selection studies revealed a very low propensity for resistance, with modest loss of potency 51 
mediated via point mutations in PfACG1 and PfEHD. These proteins are implicated in intracellular 52 
trafficking, lipid utilization and endocytosis, suggesting interference with these pathways as a novel 53 
mode of action. This declared preclinical candidate offers the potential for a single low-dose cure for 54 
malaria.  55 
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INTRODUCTION 56 
Worldwide, malaria mortality and incidence were estimated to decrease by 60% and 37% 57 
respectively from 2000 to 2015. This positive trend came to an end in 2016, with cases and deaths 58 
plateauing and 229 million cases and 409,000 deaths estimated in 2019 (1). P. falciparum parasite 59 
resistance to first-line Artemisinin-based Combination Therapies (ACTs) continues to be on the rise 60 
in Southeast Asia and now threatens Africa (2-4). Despite extensive worldwide initiatives, malaria 61 
drug discovery and development efforts have encountered major obstacles to identifying new agents 62 
with novel modes of antiplasmodial action that do not readily succumb to parasite resistance (5).  63 
 64 
To address these barriers, we applied a novel drug discovery approach leveraging research and 65 
development programs on human diseases at Sanofi. While classic approaches rely on the 66 
identification of compounds that are both potent and specific against Plasmodium parasites, our 67 
strategy first identified Plasmodium-active compounds from a library of chemical matter with known 68 
activity against human targets selected from discovery programs through to Phase III clinical trials. 69 
Compounds active against P. falciparum asexual blood-stage parasites were then chemically 70 
optimized to increase antiplasmodial specificity and reduce host toxicity risks. Our approach led to 71 
the identification of several highly potent new chemical series, including the acylguanidines 72 
ultimately exemplified by MMV688533. This molecule was shown to act via a novel mode of action 73 
that allowed P. falciparum parasites to acquire only low-grade resistance under drug pressure.  74 
  75 
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RESULTS 76 
Identification of acylguanidines as a potent antiplasmodial chemical series with promising 77 
physicochemical properties 78 
A bioinformatics-mediated analysis of Sanofi drug discovery programs led to the selection of 450 79 
compounds active against one of 33 human targets for which putative orthologs were found in P. 80 
falciparum, Trypanosoma brucei, Trypanosoma cruzi, and/or Leishamania donovani. We also 81 
included 350 compounds active against any one of 28 Sanofi high-priority human targets. Screening 82 
of these 800 compounds against cultured P. falciparum asexual blood stage parasites identified 120 83 
compounds whose half-maximal growth inhibition concentration (IC50) was £ 1 µM, corresponding 84 
to a 15% hit rate. As a comparison, classical random screening approaches have earlier yielded 0.35-85 
0.68% hit rates (6-8), highlighting the benefit of our drug discovery strategy. We then applied hit 86 
selection criteria including suitable physicochemical properties (https://www.mmv.org/research-87 
development/information-scientists) and IC50 values <1 µM against a panel of drug-sensitive or -88 
resistant P. falciparum strains, and screened an additional set of 800 analogs of preferred hits to 89 
expand Structure-Activity Relationships (SAR) (9). This work yielded six chemical scaffolds for 90 
medicinal chemistry optimization. Here we describe the acylguanidine series, which includes the 91 
initial hit MMV668603 that was exquisitely potent against P. falciparum NF54 asexual blood stages, 92 
with an IC50 of 1.7 nM. This hit originated from the dimerization of a compound chemically related 93 
to Cariporide, an inhibitor of human Na+/H+ exchanger isoform 1 (NHE1) that has anticancer and 94 
cardioprotective properties (10, 11). A hit to lead optimization program, including SAR studies, led 95 
to the intermediate compound MMV669851 and the eventual preclinical candidate MMV688533 96 
(Fig. 1A). Compared to MMV668603, the candidate MMV688533 does not contain a diazo moiety, 97 
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shows improved solubility (from <10 µg/mL to >1,000 µg/mL at pH 1) and intestinal permeability, 98 
and retains potent antiplasmodial activity (Fig. 1A; Tables S1A, S1B).  99 
 100 
MMV688533 displayed fast asexual blood stage parasite killing rate and high potency against 101 
P. falciparum and P. vivax strains in vitro and ex vivo 102 
MMV688533 was highly potent against multiple P. falciparum strains, with IC50 values in the low 103 
nanomolar range and no evidence of reduced potency against parasite lines resistant to antimalarials 104 
currently in the clinic or in development (Table S1C). These data suggest that MMV688533 might 105 
have a distinct mode of antiplasmodial action. MMV688533 also showed excellent ex vivo activity 106 
against asexual blood stage parasites from fresh P. falciparum isolates from Ugandan patients 107 
(median IC50 = 1.3 nM, range 0.02 – 6.3 nM, N=143). In Papua Indonesia, where both P. falciparum 108 
and P. vivax are endemic, MMV688533 remained potent in ex vivo assays, with similar IC50 values 109 
against both parasite species (medians of 18.9 and 12.0 nM respectively; Table 1). MMV688533 110 
was as potent if not more so than either chloroquine or piperaquine against P. falciparum and P. 111 
vivax clinical field isolates (Table 1). This compound did not show potent activity against P. 112 
falciparum liver stages or male and female gametes (Table S1D). 113 
 114 
MMV688533 displayed a fast-killing profile in the parasite reduction rate (PRR) assay (12), as 115 
demonstrated by a log10 PRR of nearly 5, corresponding to a decrease of parasitemia by nearly 5 116 
orders of magnitude during a single 48 h intra-erythrocytic developmental cycle (Fig. 1B). This 117 
profile is similar to dihydroartemisinin, the active metabolite of artemisinins that constitute the 118 
fastest-acting class of antimalarials available to date (13). This compound displayed very rapid 119 
 - 7 - 7 
parasite killing when tested over the range of 1-30´ IC50 (Fig. 1C), as well as very low cytotoxicity 120 
(Table S1E).  121 
 122 
MMV688533 displayed fast and potent in vivo efficacy and favorable in vitro ADME and in 123 
vivo PK properties 124 
MMV688533 was highly efficacious in the NOD-SCID IL2Rγnull mouse model of P. falciparum 125 
asexual blood-stage infection (14), with a single oral dose of 5 mg/kg resulting in a rapid reduction 126 
in parasitemia to below the limit of detection within 48 h, followed by recrudescence to 1% by day 127 
18. By comparison, vehicle-treated mice attained a lethal parasitemia of 8-10% by day 5 (Fig. 1D). 128 
These data predicted an ED90 of 2 mg/kg, corresponding to the single dose required to reduce 129 
parasitemia by >90% by day 7 compared to vehicle-treated mice (Fig. 1D, 1E; Table S1F). Four 130 
consecutive daily doses of 0.9 mg/kg produced >90% reduction in parasitemia by day 7 (data not 131 
shown). Importantly, one dose of at least 5 mg/kg MMV688533 cleared parasites as rapidly as 50 132 
mg/kg dihydroartemisinin (Fig. 1D). Pharmacokinetic-pharmacodynamic (PK/PD) modeling 133 
predicted an in vivo minimal parasiticidal concentration of 20.3 ng/mL (Table S1G).  134 
 135 
PK studies indicated a low plasma clearance (CL) in mice, rats and dogs (Table S1H). When tested 136 
on purified cytochrome P450 enzymes, MMV688533 did not show high inhibitory potency (Table 137 
S1I).  MMV688533 also displayed a moderate to high volume of distribution (Vss: 1.4 L/kg in mice, 138 
4.7 L/kg in Beagle dogs), and a moderate to long half-life in all species (3.2 h in mice, 50.7 h in 139 
dogs) (Table S1J; Table S1N). The oral bioavailability of MMV688533 was >70% in rodent species 140 
(Table S1J). Human CL and Vss parameters calculated from rat and dog allometry were predicted to 141 
be inferior to 5% of the hepatic blood flow using two methods (see Methods section) and 5.0 L for a 142 
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70 kg patient, respectively. The predicted half-life of MMV688533 in humans was greater than 100 143 
h (Table S1P).  144 
 145 
We then predicted the efficacious single dose in humans based on: (i) the minimal parasiticidal 146 
concentration derived from PK/PD modeling of the Pf NOD-SCID data (Tables S1F; S1G); (ii) the 147 
Kkill derived from in vitro PRR studies (Fig. 1B); (iii) the PK in mouse, rat and dog used in allometric 148 
scaling (Tables S1J-S1P); and (iv) a biopharmaceutical model (GastroPlus®). This latter model 149 
predicted that at least 50% of a 500 mg dose was absorbed when administered in fed conditions. A 150 
100 mg dose is absorbed up to 70% in fasted conditions while at this dose, the food effect is less than 151 
30% (data not shown). Using these parameters, a single oral administration of 30 mg MMV688533 152 
in humans was predicted to maintain its concentration above the minimal parasiticidal concentration 153 
over a period of 96 h, which covers two P. falciparum erythrocytic replication cycles, and to reduce 154 
parasitemia by at least 6 logs when a conservative in vitro log PRR value was capped at 3.  Similarly, 155 
a dose of 24 mg was predicted to reduce parasitemia when the in vitro log PRR value of 5 was used. 156 
A single-dose treatment with 66 mg of MMV688533 was predicted to reduce parasitemia by 12 logs, 157 
suggesting very favorable characteristics for future clinical studies. 158 
 159 
MMV688533 revealed a favorable tolerability profile 160 
In silico toxicity predictions did not raise any safety alerts other than a moderate phototoxic risk 161 
(Table S1Q), which proved minimal when tested in MMV688533-treated BALB/c 3T3 mouse 162 
fibroblasts exposed to UV light. Genotoxicity testing with MMV688533, including preliminary 163 
Ames and micronucleus assay were negative. Profiled on a receptor/enzyme panel, MMV688533 164 
displayed micromolar affinity for calcium and chloride channels as well as for benzodiazepine and 165 
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dopamine receptors (Table S1R). Considering its similarity with cariporide, cardiovascular 166 
parameters were assessed in detail. MMV688533 had a modest effect on the hERG channel with an 167 
IC50 of 30 µM (data not shown) and 4.6 µM when measured by automatic and manual Patch-Clamp 168 
(Table S1S), respectively. Inhibition studies with Nav1.5 and Cav1.1 ion channels yielded IC50 169 
values of 14 µM and 2.1 µM, respectively (Table S1S). When tested in the Pukinje fiber assay, 170 
MMV688533 induced mild effects that were not suggestive of a torsadogenic profile. However, 171 
because of the limited solubility of the compound in the conditions of this study, a full cardio-safety 172 
in vitro evaluation at higher concentrations was not possible. Therefore, in vivo studies were 173 
conducted to better assess potential cardiovascular safety risks. Continuous intravenous 174 
administration of MMV688533 (at 10, 20 and 30 mg/kg) to anesthetized guinea pigs did not affect 175 
blood pressure, heart rate, the ECG RR or QT intervals, or the QRS complex (data not shown). In 176 
summary, in silico, in vitro and in vivo safety studies with MMV688533 did not raise any measurable 177 
cardiotoxicity alerts. 178 
 179 
Preliminary safety was assessed in rats and dogs via oral treatment and drug exposure measurements 180 
(Toxicokinetics: Tables S1T, S1U). In a non-GLP 2-week toxicity study in Sprague-Dawley rats, 181 
no clinically apparent changes were observed at 12.5, 25 and 50 mg/kg dose levels. 12.5 mg/kg/day 182 
exposure was considered the No-Observed Effect Level (NOEL) in this study due to an increase of 183 
liver biomarkers and microscopic changes (foamy macrophages, microscopic changes) at the two 184 
highest doses. In a non-GLP 2-week toxicity study in beagle dogs, (0.5 and 1 mg/kg/day once daily 185 
and 2 mg/kg/day every other day), only minimal transient changes of no safety concern were 186 
detected. In conclusion, the no-observed-adverse-effect level (NOAEL) was declared at 1 mg/kg and 187 
the corresponding cumulated exposure over 14 days was 14-fold higher than that predicted for a 30 188 
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mg single dose in humans (Table S1V). Such a predicted safety margin was judged promising 189 
enough to progress MMV688533 to more detailed regulatory preclinical studies before first-in-190 
human clinical trials. 191 
 192 
MMV688533 is maximally potent against P. falciparum rings and early trophozoite stages 193 
To assess the timing of MMV688533 action, we employed an in vitro asexual blood stage 194 
susceptibility assay that measures compound activity against early and late rings, early and late 195 
trophozoites, and schizonts (15). The assay was validated by the stage-specific susceptibility profiles 196 
of dihydroartemisinin, chloroquine and the PI4K inhibitor KAI407 (16), which showed the expected 197 
peak activities on early rings, rings and trophozoites, and schizonts, respectively (15). MMV688533 198 
and dihydroartemisinin shared a similar activity profile, with early rings to early trophozoites being 199 
the most susceptible, whereas schizonts were the least affected (Fig. 2A). 200 
 201 
Ramping selections with P. falciparum asexual blood stage parasites yield low-grade resistance 202 
to MMV688533 203 
To identify possible resistance mechanisms to the acylguanidine MMV688533, we performed single-204 
step in vitro resistance selections by exposing triplicate flasks of 2´109 wild-type Dd2-B2 parasites 205 
to 3×IC50 of MMV688533. These single-step selections did not yield resistant parasites after 60 days, 206 
suggesting a low propensity for resistance development for this compound. This was further 207 
confirmed in ramping selections, which entailed gradually increasing the drug pressure from 1 to 208 
11´ IC50 on triplicate flasks of 2´108 3D7-A10 parasites each over a six-month period. This selection 209 
yielded only very low-grade resistance, with a 2 to 5-fold IC50 increase in each of the three drug-210 
pressured lines (Fig. 2B; Table 2). Whole-genome sequencing (WGS) of four resistant clones 211 
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obtained from across the three pressured lines identified single nucleotide polymorphisms (SNPs) in 212 
five genes: a conserved Plasmodium protein of unknown function (PF3D7_0910300); an EH 213 
domain-containing protein (EHD; PF3D7_0304200); a conserved Plasmodium protein of unknown 214 
function (PF3D7_0510100); a putative RNA pseudouridylate synthase (PF3D7_0511500); and the 215 
putative ATP synthase (C/AC39) subunit (PF3D7_1464700) (Table 2; Table S3).  216 
 217 
Of note, all four clones (sel. 533-CL1 – CL4, named after the last three digits of the selecting 218 
compound MMV688533 followed by the clone name), carried G98V (clones sel. 533-CL1 and sel. 219 
533-CL4), W286R (clone sel. 533-CL2) or T92* stop codon (clone sel. 533-CL3) mutations in 220 
PF3D7_0910300, identified from three separately drug-pressured lines, suggesting a key role for this 221 
protein in conferring resistance to MMV688533. PF3D7_0910300, which we herein name 222 
Plasmodium falciparum acylguanidine 1 (PfACG1) in reference to the  acylguanidine series, is a 223 
conserved Plasmodium protein of unknown function. Clone sel. 533-CL4, which also has a D218Y 224 
mutation in gene PF3D7_0304200 (PfEHD), displayed the highest level of resistance to 225 
MMV688533 (4.6-fold IC50 shift) (Fig. 2B; Table 2). This suggested an additional role for PfEHD 226 
in enhancing parasite resistance to the compound. Based on these observations, the presence of 227 
PfACG1 mutations in all the selected clones and the boost in resistance conveyed by an additional 228 
PfEHD D218Y mutation in sel. 533-CL4, we hypothesized that these two proteins, out of the five 229 
proteins identified using WGS, play a crucial role in mediating resistance to MMV688533. We chose 230 
to not assess the other three genes listed above as each harbored a mutation observed from only a 231 
single line, and unlike PF3D7_0304200 none of these three were associated with an increased degree 232 
of resistance (Table 2).   233 
 234 
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To test this hypothesis, we introduced the G98V and W286R mutations in PfACG1 and the D218Y 235 
mutation in PfEHD individually into wild-type 3D7-A10 parasites using a CRISPR/Cas9 gene-236 
editing strategy. This yielded the edited lines ed. 3D7 ACG1G98V, ed. 3D7 ACG1W286R and ed. 3D7 237 
EHDD218Y lines respectively. The G98V mutation in the ed. 3D7 ACG1G98V line conferred 238 
comparable levels of resistance to the corresponding selected clone sel. 533-CL1, whereas the 239 
W286R mutation in ed. 3D7 ACG1W286R line only contributed around half of the resistance observed 240 
in sel. 533-CL2 (Fig. 2B; Table 2). The D218Y mutation in PfEHD alone was insufficient to confer 241 
resistance. To test whether SNPs in PfACG1 are needed to obtain higher grade resistance to 242 
MMV688533 we introduced the D218Y mutation into the background of the clone sel. 533-CL1, 243 
using a CRISPR/Cas9 strategy. This clone harbors the G98V mutation in PfACG1. The resulting sel. 244 
ed. 533-CL1EHD-D218Y line showed a 6.2-fold shift in IC50 compared to wild-type parasites, 245 
comparable to the 4.6-fold shift in clone sel. 533-CL4. These results provide evidence that the 246 
D218Y mutation in PfEHD enhances resistance to MMV688533 only when the G98V mutation is 247 
already present in PfACG1.  248 
  249 
Conditional knockdown of the resistance determinants PfACG1 and PfEHD does not affect in 250 
vitro parasite growth 251 
To further explore the role of PfACG1 and PfEHD, we engineered conditional knockdown parasite 252 
lines in which we could regulate protein expression levels via the TetR-DOZI system (17). Normal 253 
protein levels were maintained by culturing parasites in the presence of anhydrotetracycline (aTc) 254 
(Fig. S1A). Western blot analysis of these lines, which harbored a C-terminal 2´HA epitope tag 255 
fused to each gene product, confirmed the expression of PfACG1 and PfEHD in the presence of aTc 256 
(Fig. 2C; Fig. S1B). aTc withdrawal resulted in the loss of protein expression, confirming efficient 257 
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knockdown of the proteins. Despite the substantial knockdown observed from the Western blots, 258 
assessment of growth over two replicative cycles revealed that PfACG1 and PfEHD parasite lines, 259 
maintained in the absence of aTc, were able to progress through the intra-erythrocytic stage life cycle 260 
similar to controls, suggesting that loss of function of both proteins does not affect viability under 261 
normal culture conditions (Fig. 2C). To test for ex vivo compound-target interactions, we determined 262 
the IC50 of MMV688533 against wild-type versus knockdown conditions of PfACG1 and PfEHD. 263 
Similar to an unrelated control line, knockdown of PfACG1 and PfEHD did not result in differential 264 
susceptibility to MMV688533 (Fig. 2D), providing evidence that these proteins are not directly 265 
targeted by MMV688533. 266 
 267 
MMV688533-resistant parasites do not show cross resistance to current antimalarials 268 
To test whether resistance to MMV688533 might impact the efficacy of clinical antimalarials, we 269 
tested the 3D7 ACG1G98V and 3D7 ACG1W286R edited lines as well as the high-grade resistant clone 270 
sel. ed. 533-CL1EHD-D218Y for cross-resistance against a diverse panel of eleven known antimalarials. 271 
This study employed 72 h asexual blood stage parasite susceptibility assays across a range of drug 272 
concentrations (Fig. 2E; Table S2). Neither the individual G98V and W286R mutations in PfACG1 273 
nor the multiple SNPs in sel. ed.  533-CL1EHD-D218Y conferred cross-resistance to these drugs, 274 
implying that MMV688533 has a novel mode of action against P. falciparum. 275 
 276 
PfACG1 and PfEHD localize primarily to distinct intracellular parasite vesicles 277 
To interrogate the subcellular localization of PfACG1 and PfEHD we performed 278 
immunofluorescence studies with a variety of cellular co-markers. We generated a doubly tagged 279 
recombinant NF54attB parasite line expressing a 3×HA tag at the C-terminus of the PfEHD 280 
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endogenous locus as well as a stably-integrated transgenic copy of PfACG1 that was C-terminally 281 
tagged with eGFP (NF543×HA-EHDattB-ACG1-eGFP).  282 
 283 
PfACG1-eGFP mainly localized to foci around the digestive vacuole (DV) of the parasite with 284 
residual labeling observed around the parasite nucleus (Fig. 2F; Fig. S4, S6). PfEHD likewise 285 
appeared in foci that localized mostly to the parasite periphery as well as close to the DV; other foci 286 
were also other observed, although to a lesser extent, throughout the parasite cytoplasm (Fig. 2F; 287 
Fig. S5, S7). Co-labeling using anti-HA and anti-GFP antibodies to assess co-localization of 288 
PfACG1 with PfEHD showed no overlap between the two fluorophores (Fig. 2G).  289 
 290 
Since most of the eGFP signal for the PfACG1-fusion protein was observed adjacent to the DV we 291 
performed co-stains using antibodies directed to PfCRT, PfMDR1 or Plasmepsin II, which are 292 
known to localize to the DV (Fig. 2H; Fig. S4A-B, S6B-C). This confirmed proximity to the DV, 293 
but only showed infrequent, seemingly random overlap between PfACG1 and either of the DV 294 
transmembrane proteins PfCRT and PfMDR1. To investigate whether PfACG1 could overlap with 295 
neutral lipid bodies, which are often localized adjacent to the parasite DV (18), we carried out co-296 
stains using LipidTOX and Nile Red (Fig. 2I; Fig. S4C-F, S6D-G). Although not all eGFP positive 297 
foci exclusively overlapped with these lipid bodies we observed frequent juxtaposition. These 298 
observations point to the possibility that PfACG1 partially associates with lipid storage bodies 299 
localized close to the DV. Despite our detection of an eGFP signal close to the nucleus, no overlap 300 
was detected when co-staining for the parasite endoplasmic reticulum (ER) using antibodies specific 301 
for PDI (protein disulfide isomerase; Fig. 2J; Fig. S6H-I). Instead, the eGFP signal showed some 302 
overlap with antibodies to ERD2 and PMT (phosphoethanolamine N-methyltransferase), which 303 
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represent markers for the cis- and trans-Golgi (19, 20), respectively (Fig. 2K; Fig. S4G-J, S6J-K). 304 
To test whether PfACG1 localized to Rab-positive vesicles that are known mediators of vesicular 305 
traffic, we co-stained with Rab5A, 5B and Rab7 antibodies. We only observed infrequent overlap, 306 
similarly to co-stains performed with antibodies against K13, a marker for hemoglobin endocytosis 307 
(21, 22) (Fig. 2L; Fig. S4K-N, S6L-O). Along these lines no colocalization was observed for 308 
PfACG1 and coronin, a protein involved in F-actin organization that has recently been associated 309 
with in vitro resistance of early ring stages to artemisinins (23) (Fig. S4O).  Lastly, we assessed co-310 
localization to the parasite mitochondrion using MitoTracker Deep Red, as well as to the apicoplast 311 
as visualized with anti-ACP antibodies. No overlap was observed between PfACG1-eGFP and those 312 
organelles (Fig. S4P,Q). 313 
 314 
Similar to our observations with PfACG1, we detected PfEHD-positive foci that were close to the 315 
DV but did not co-localize with PfCRT (Fig. 2M; Fig. S7B-C). Co-stains using LipidTOX 316 
occasionally co-localized some of the HA-labeled PfEHD vesicles with neutral lipid bodies (Fig. 317 
2N; Fig. S5A-B, S7D). To investigate PfEHD association with the parasite ER as well as the Golgi 318 
apparatus we used anti-PDI antibodies or anti-ERD2 and anti-PMT antibodies respectively. Frequent 319 
proximity and partial overlap were observed between PfEHD positive foci and the ER-resident 320 
markers PDI and BIP, whereas the Golgi stains revealed no obvious association between PfEHD and 321 
this organelle (Fig. 2O-P; Fig. S5C-F, S7E-H). In mammalian cells, EH domain (EHD)-containing 322 
proteins, serving as protein interaction platforms, are known to primarily function as key regulators 323 
in endocytosis (24). To explore whether PfEHD could play a similar role in protein and lipid 324 
trafficking processes in parasites we performed immunofluorescence (IFA) studies using antibodies 325 
to coronin and Rab proteins. We found that PfEHD vesicles that localized close to the parasite 326 
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membrane frequently overlapped with coronin, hinting at a possible interaction between the two 327 
proteins (Fig. 2Q; Fig. S5G-J, S7I-J). Immunofluorescence assays carried out with the panel of Rab 328 
antibodies (anti-Rab5A, 5B, 5C, Rab7 and Rab11A) as well as antibodies to K13 revealed some 329 
juxtaposition of Rab-positive vesicles and K13-positive foci with PfEHD (Fig. S5K-P, S7K). In 330 
contrast, when assessing potential PfEHD association with the apicoplast using anti-ACP antibodies, 331 
we did not observe overlap between the fluorophores (Fig. S5Q). 332 
 333 
DISCUSSION 334 
Here, we report an exquisitely potent antimalarial, MMV688533, discovered among Sanofi 335 
compounds active on defined human targets and that were assayed for potency against P. falciparum 336 
asexual blood stage parasites. Our screen of 800 compounds yielded a high hit rate, with 120 showing 337 
submicromolar antiplasmodial activity. Physicochemical analysis identified acylguanidines as the 338 
most promising series, with subsequent structure analysis relationship (SAR)-based lead 339 
optimization yielding MMV688533. Parasite reduction ratio assays revealed exceptionally fast 340 
killing, with MMV688533 reducing the parasite load by >3 log within 24 h after drug addition, 341 
similar to dihydroartemisinin and considerably faster than the comparator first-line drugs 342 
chloroquine and pyrimethamine. MMV688533 also displayed minimal toxicity against mammalian 343 
cells, slow clearance, and a long half-life predicted at 100 h in humans.  Single-dose efficacy in the 344 
P. falciparum-infected SCID mouse model was excellent, with parasite clearance and delayed 345 
recrudescence observed at doses as low as 5 mg/kg. These data highlight the therapeutic potential of 346 
this novel class of antimalarials.  347 
 348 
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Whole-cell screens for antimalarials have in recent years yielded multiple potent antimalarials that 349 
despite their promise have encountered parasite resistance at frequencies and levels that pose an 350 
important concern for their further development as curative drugs (25). For example, inhibitors of 351 
the drug targets PfATP4 or PfeEF2 can select for resistance from as a few as 106-107 parasites, with 352 
SNPs causing IC50 increases of up to several hundred-fold ((26-28); unpublished results). In contrast, 353 
using these same selection procedures (29), MMV688533 yielded no resistance when used to 354 
pressure even large parasite inocula (6´109). Low-grade resistance could only be achieved using a 355 
ramping method of gradually increasing drug concentrations over a 6-month period. Parasite clones 356 
from these selections showed 2- to 5-fold higher IC50 values against MMV688533. Whole-genome 357 
sequencing identified two distinct point mutations or a stop codon in the PfACG1 gene in all clones 358 
assayed from three independent selections. Upon gene editing, both point mutations afforded only a 359 
2-fold IC50 increase. One clone also harbored a point mutation in PfEHD, which upon editing into a 360 
PfACG1 mutant line resulted in a 6-fold higher IC50 relative to the drug-sensitive 3D7 line. Other 361 
editing results showed that this PfEHD mutation on its own was insufficient to mediate parasite 362 
resistance. We note that three other genes were observed to each harbor a single non-synonymous 363 
mutation. These mutations occurred separately in only one of the three flasks and may be attributable 364 
to stochastic events that arise naturally at low frequency during extended in vitro culture (30, 31). 365 
 366 
PfACG1 and PfEHD are both considered to be dispensable for P. falciparum asexual blood stage 367 
growth in vitro (32), consistent with our cKD data in which no evident growth inhibition occurred 368 
despite virtually complete protein knockdown (Fig. 2C). PfACG1, previously annotated as a 369 
conserved protein of unknown function, is only conserved among Apicomplexan parasites of the 370 
genus Plasmodium, with minimal (~ 20%) amino acid identity to Cryptotosporidium andersoni and 371 
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C. muris. Protein sequence analysis shows a signal peptide at the N-terminus and a single 372 
transmembrane domain at the C-terminal end. Little else is known about this protein. PfEHD 373 
contains a highly-conserved Eps15 homology domain (EHD) involved in protein-protein interactions 374 
and found in proteins that play a key role in endocytosis (24). PfEHD has previously been linked to 375 
vesicular trafficking in P. falciparum parasites (33).  376 
 377 
PfACG1 and PfEHD did not co-localize in our immunofluorescence assays. Nonetheless, PfACG1 378 
co-localized with the neutral lipid markers LipidTOX and Nile Red, as well as the Golgi markers 379 
ERD2 that mediates protein retention in the ER and PMT that plays a critical role in 380 
phosphatidylcholine synthesis, suggesting its role in vesicular trafficking or storage of lipids. In 381 
contrast, PfEHD showed some co-localization with the ER markers ERD2 and PDI as well as the 382 
actin-binding protein coronin. PfEHD has previously been shown to be an interacting partner of AP-383 
2µ, an adapter protein that is essential for endocytosis and intracellular trafficking (34). Taken 384 
together, these data suggest that PfACG1 and PfEHD might be involved in related intracellular 385 
trafficking pathway(s) acted upon by MMV688533, which would be consistent with our observation 386 
that mutations in both proteins contributed to resistance to this compound. These results, along with 387 
lack of chemical-genetic interaction observed using the cKD lines (Fig. 2C), suggest that neither of 388 
these two proteins is the actual target and function instead as resistance mediators. These data suggest 389 
that MMV688533’s mode of action involves inhibition of vesicular trafficking and/or lipid storage 390 
pathways. At present this compound can be considered “target-less”, a feature shared by many 391 
antimalarials in clinical use or advanced stages of development, including lumefantrine, quinine, 392 
artemisinin derivatives, OZ439, and KAF156 (25, 35). Further studies are clearly required to define 393 
the mode of action of MMV688533.  394 
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 395 
In conclusion, we report the novel acylguanidine MMV688533 with favorable fast-acting and long-396 
lasting pharmacokinetic/pharmacodynamic properties. Drug selection studies showed that parasites 397 
could only acquire low-grade resistance with large inocula, and no cross-resistance was observed 398 
with established antimalarials or advanced preclinical candidates. These data suggest a novel mode 399 
of action for MMV688533, which appears to involve lipid-associated intracellular trafficking of 400 
essential components. The promising preclinical therapeutic margin and very low single doses 401 
predicted to be efficacious in humans should improve compliance and enable a low cost of goods. 402 
Further safety and pharmacological preclinical evaluations are currently ongoing to support the 403 
initiation of human clinical trials.  404 
 405 
MATERIALS AND METHODS 406 
Study design 407 
This study’s objective was to harness the potential of compounds with known drug-like properties, 408 
which had been successful in fueling discovery and development pipelines in several therapeutic 409 
areas, as a source of potential antimalarial candidates with novel modes of actions. Screening 410 
against P. falciparum asexual blood stage parasites led us to identify an acylguanidine chemical 411 
series with good potency and physicochemical properties. Medicinal chemistry yielded analogs 412 
with improved parasite selectivity and pharmacokinetic properties. Prioritized compounds were 413 
assayed for in vivo efficacy in a humanized mouse model of P. falciparum infection. Preclinical 414 
toxicity studies with 4- or14-day exposures were then performed in rats and dogs to predict a safety 415 
margin for clinical use. Cross-resistance and drug selection studies were used to test for resistance 416 
liabilities. Conditional knockdown and gene editing experiments, along with immunofluorescence 417 
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imaging, were leveraged to explore compound mode of action. All assays were performed with 418 
multiple repeats with technical duplicates or triplicates, with positive and negative controls, as 419 
indicated in the Materials and Methods and in Figure legends.  420 
 421 
MMV688533 synthesis 422 
MMV688533 was synthesized as described in the Supplementary Materials and Methods and 423 
illustrated in Fig. S8.  424 
 425 
Compound potency against P. falciparum and P. vivax parasites  426 
Antimalarial activity against resistant culture-adapted strains of P. falciparum and clinical field 427 
isolates was performed with the modified [3H]-hypoxanthine incorporation assay, as previously 428 
reported (36). Ex vivo potency against P. falciparum and P. vivax clinical isolates was determined 429 
as described in the Supplementary Materials and Methods. 430 
 431 
Determination of the in vitro rate of killing (parasite reduction ratio, PRR)  432 
As described in (12), the compound IC50 was determined via [3H]-hypoxanthine incorporation. For 433 
PRR assays, 105 3D7A parasites cultures were exposed to MMV688533 at 10×IC50 for 120 h. Drug 434 
treatment was renewed every 24 h over the entire period. Parasite aliquots were taken from the treated 435 
cultures every 24 h, with drug washout, throughout the 5-day treatment period. Fresh RBC and new 436 
media were then added to the drug-free parasites, which were serially diluted in quadruplicate into 437 
96 well plates. Growth in individual wells was detected after 3 and 4 weeks using [3H]-hypoxanthine 438 
incorporation. The number of viable parasites was determined by the dilution down to which growth 439 
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was observed. The rate of killing was represented by the log of viable parasites as a function of 440 
treatment duration. PRR was defined as the log-linear reduction of viable parasites over 48 h. 441 
 442 
Determination of efficacy and pharmacokinetic profiles in the Pf SCID mouse model  443 
Assays used the P. falciparum Pf3D70087/N9 line (14), which was propagated in 23-28 gram female 444 
NOD-scid IL-2Rγnull mice (NSG) (Charles River, France) or NOG-scid IL-2Rγnull mice (NOG) 445 
(Taconic, Denmark) at The Art of Discovery (TAD). In vivo efficacy trials are described in the 446 
Supplementary Materials and Methods. 447 
 448 
Parasite stage-specificity assays  449 
In vitro IC50 values were determined by incubating parasites for 72 h across a range of 10 different 450 
concentrations of antimalarial compounds plus two no-compound controls. Stage-specificity assays 451 
used a modified protocol with tightly-synchronized parasites tested at different starting stages of the 452 
ABS cycle (15).  453 
 454 
P. falciparum resistance selections  455 
Single-step selections for MMV688533 resistance employed triplicate flasks of 2´109 Dd2-B2 456 
parasites exposed to 5-14´ the IC50 (25–80 nM) of MMV688533. Selections were terminated after 457 
60 days as resistant parasites had not emerged. Ramping selections used triplicate flasks of 2´108 458 
3D7-A10 parasites exposed to MMV688533 at concentrations that increased gradually from 1-10´ 459 
the IC50 (5.5–60 nM) over a six-month period. Resistant clones were obtained from the bulk cultures 460 
of the ramping selections by limiting dilution, and four clones were selected for whole-genome 461 
sequencing. MMV688533 growth inhibition was determined by staining the parasites with SYBR 462 
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Green and MitoTracker Deep Red (Life Technologies) followed by flow cytometry (Accuri C6, BD 463 
Biosciences) (37). IC50 values were derived from growth inhibition data using nonlinear regression 464 
(Prism 9.0, GraphPad). Unless stated otherwise, all drug assays were performed on at least four 465 
separate occasions (as biological repeats) with two technical replicates.  466 
 467 
Whole-genome sequencing analysis and genome editing  468 
The 3D7-A10 parent and MMV688533-resistant clones were subjected to whole-genome sequencing 469 
using an Illumina TruSeq DNA PCR-Free library preparation protocol and a MiSeq sequencing 470 
platform, as described (38). CRISPR/Cas9 and mycobacteriophage Bxb1 serine integrase system-471 
based gene editing, including cKDs, is detailed in the Supplementary Materials and Methods. 472 
 473 
Immunofluorescence assays 474 
Protein localization assays were performed as described (22), (Supplementary Materials and 475 
Methods). 476 
 477 
Statistical analysis 478 
Mann-Whitney U tests were performed (using Prism 9.0; GraphPad) to test for statistical 479 
significance between isogenic parasite lines in their drug IC50 values (Fig. 2B; Table S2). 480 
Wilcoxon rank sum tests were used to identify significant differences in drug susceptibility 481 
between P. falciparum field isolates (Table 1).  482 
  483 
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Clinical field isolates 
(Uganda) 
Clinical field isolates 
(Papua, Indonesia) 
Clinical field isolates 
(Papua, Indonesia) 
















MMV688533 1.9 (4) 3.0 (4) 9.7 (2) 19 (2) 1.3 (143; 0.02 - 6.3) 18.9 (15; 5.3-39.2) 12.0 (6; 5.4-19.9) 
Chloroquine 11 (11) 347 (10) 10.9 (2) 100.3 (2) 17*** (143; 2.1 - 346) 64.8*** (15; 38.3-283) 36.4* (6; 11.6-114) 
Piperaquine 4.4 (11) 7.9 (10) 25.8 (2) 111.2 (2) 5.1*** (140; 0.3 - 26) 60.8*** (15; 17.6-130) 46.6* (6; 15.0-135) 
Mefloquine 4.8 (11) 6.6 (10) 37.2 (2) 8 (2) 8.3*** (120; 0.5 - 24) 10.0 (15; 4.9-41.9) 11.2 (6; 8.1-20.7) 
DHA/artesunatea 1.9 (9) 1.7 (9) 0.6 (2) 1.1 (2) 1.5 (142; 0.1 - 9.0) 1.2*** (15; 0.4-4.3) 0.6* (6; 0.3-2.4) 
In vitro activity against Plasmodium culture-adapted lines or field isolates was calculated from dose-response curves and is shown as 565 
median or mean half-maximal growth inhibition concentrations (IC50 values) in nM. For the laboratory lines, numbers of independent 566 
repeats are shown in brackets. 3D7 and FC27 are chloroquine-sensitive whereas Dd2 and K1 are chloroquine-resistant. Potency of the 567 
other antimalarials was compared to MMV688533 using a Wilcoxon rank sum test. *p<0.05; ***p<0.001. aDHA was tested on 3D7, 568 
Dd2 and Ugandan parasites, whereas artesunate was tested on FC27, K1 and Papua/Indonesian parasites. 569 
  570 
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Table 2. Mutations identified in MMV688533-selected resistant P. falciparum clones and validated using CRISPR/Cas9 gene editing. 571 
Gene product Gene ID 
   
Amino acid 
substitution 

















3.1× IC50 1.7× IC50 2.5× IC50 4.6× IC50 1.8× IC50 1.2× IC50 2.2× IC50 6.2× IC50 
Conserved Plasmodium 
protein (PfACG1) 
PF3D7_0910300 W286R W286R T92* G98V G98V wt G98V G98V 
EH domain-containing 
protein (PfEHD) 
PF3D7_0304200 wt wt wt D218Y wt D218Y wt wt D218Y 
Conserved Plasmodium 
protein 
PF3D7_0510100 wt wt wt wt wt wt N1042H N1042H 
RNA pseudouridylate 
synthase, putative 
PF3D7_0511500 wt wt K2762E wt wt wt wt wt 
ATP synthase (C/AC39) 
subunit, putative 
PF3D7_1464700 L260I wt wt wt wt wt wt wt 
Four parasite clones (sel. 533-CL1 from flask 1, sel. 533-CL2 and 533-CL3 from flask 2, and sel. 533-CL4 from flask 3) were generated 572 
from selections (sel.), and named after the last 3 digits of the selecting compound (MMV688533) followed by the clone number. These 573 
clones were then chosen for whole-genome sequencing. Fold IC50 increases compared to the parent 3D7-A10 are indicated below the 574 
clone names. P. falciparum ACG1W286R, ACG1G98V and EHDD218Y strains were gene edited (ed.) using CRISPR/Cas9 to introduce the 575 
designated mutation into 3D7-A10 parasites. The sel. ed. 533-CL1EHD-D218Y clone was generated by CRISPR/Cas9 editing the EHD D218Y 576 
mutation into the selected 533-CL1 clone. wt: wild-type, *: stop mutation resulting from a deletion-induced frameshift.577 
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FIGURE LEGENDS 578 
Fig. 1. The preclinical antimalarial candidate MMV688533 has a fast rate of antiplasmodial 579 
activity that offers potent single-dose activity against P. falciparum infection in a humanized 580 
mouse model. (A) Structural representation showing the optimization of the acylguanidine series 581 
from the initial hit MMV668603 and the lead MMV669851 to the candidate MMV688533. (B) Mean 582 
± SD values of viable P. falciparum parasites determined daily for 5 days after in vitro incubation 583 
with MMV688533 at 10´ the IC50. Dihydroartemisinin, Chloroquine, pyrimethamine and 584 
atovaquone were included as reference antimalarial drugs. (C) Mean ± SD values of P. falciparum 585 
viability determined daily for 5 days following MMV688533 treatment at doses corresponding to 586 
1´, 3´, 10´ or 30´ the IC50. (D) Compound efficacy was assessed by measuring the initial clearance 587 
and time of recrudescence of P. falciparum in the peripheral blood of humanized mice administered 588 
single doses of MMV688533 ranging from 0.5 mg/kg to 75 mg/kg (two mice per dose). DHA (50 589 
mg/kg) and vehicle were included as controls. (E) Concentration of MMV688533 in serial blood 590 
samples obtained after administering different doses to P. falciparum-infected humanized mice 591 
assayed in (D). LOQ: Limit Of Quantification.  592 
 593 
Fig. 2. MMV688533 antiplasmodial activity is unrelated to existing antimalarials and selects 594 
for low-grade resistance mediated in part by mutations in PfACG1 and PfEHD. (A) In vitro 595 
asexual blood stage susceptibility assay showing MMV688533 activity in early and late rings, early 596 
and late trophozoites, and schizonts. IC50 values are shown as means ± SEM (N>3, n = 2). (B) Mean 597 
± SEM IC50 values of selected (sel.) (533-CL1, 533-CL2 and 533-CL4), edited (ed.) (PfACG1G98V, 598 
PfACG1W286R, PfEHDD218Y) lines and the sel. ed. line 533-CL1EHD-D218Y compared to the 3D7-A10 599 
parental line. N>6, n = 2; **P <0.01, ***P <0.0005; ns: not significant. (C) Western blot data 600 
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showing effective reduction in PfACG1 and PfEHD protein levels upon removal of aTc, as detected 601 
using antibodies specific to the 2´HA tag added to the C-terminus of each protein. Parasite survival 602 
was measured by quantifying expression of the integrated RLuc cassette (Fig. S1), in the presence 603 
(50 nM) or absence of aTc. Data represent the mean of three biological replicates and are normalized 604 
to a fully inhibitory concentration of chloroquine (200 nM). (D) Dose-response curves for 605 
MMV688533 against PfACG1 and PfEHD conditional knock-down (ckD) parasites expressing wild-606 
type or substantially reduced levels of each protein upon culturing with 500 nM aTc or no aTc, 607 
respectively. (E) G98V and W286R mutations in PfACG1 and a combination of both G98V in 608 
PfACG1 and D218Y in PfEHD in sel. ed. 533-CL1EHD-D218Y did not confer cross-resistance to a 609 
panel of known antimalarial drugs compared to the 3D7-A10 parent. Mean ± SEM; N>3, n = 2. (F) 610 
Fluorescence microscopy images of fixed NF543´HA-EHDattB-ACG1-eGFP parasites either stained 611 
with anti-GFP (green) antibodies or anti-HA (magenta) antibodies. Nuclei were stained with DAPI 612 
(blue). Scale bars: 2 µm. (G) Fluorescence microscopy image of fixed and doubly stained NF543´HA-613 
EHDattB-ACG1-eGFP parasites using anti-GFP (green) and anti-HA (magenta) antibodies. Nuclei 614 
were stained with DAPI (blue). Scale bars: 2 µm. (H-L) Fluorescence microscopy images and 3D 615 
reconstructions of fixed NF543´HA-EHDattB-ACG1-eGFP parasites co-stained with antibodies to anti-616 
GFP (green) and (H) anti-PfCRT antibodies, (I) LipidTOX neutral lipid stain, (J) anti-PDI, (K) anti-617 
ERD2 or (L) anti-Rab5A (red) antibodies. Nuclei were stained with DAPI (blue). Scale bars: 2 µm. 618 
(M-Q) Fluorescence microscopy images and 3D reconstructions of fixed NF543´HA-EHDattB-ACG1-619 
eGFP parasites co-stained with antibodies to anti-HA (magenta) and (M) anti-PFCRT antibodies, 620 
(N) LipidTOX neutral lipid stain, (O) anti-PDI, (P) anti-ERD2 or (Q) anti-coronin (cyan) antibodies. 621 
Nuclei were stained with DAPI (blue). Scale bars: 2 µm. 622 
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Materials and Methods 
Synthesis of MMV688533  
Step 1. Pd(PPh3)2Cl2 (4.96 g, 7.07 mmol) and cuprous iodide (1.34 g, 7.06 mmol) were added to a 
degassed solution of methyl 3-bromo-5-(trifluoromethyl)benzoate (20.0 g, 70.67 mmol) and 
trimethylsilylacetylene (17.4 g, 176.67 mmol) in 100 mL of acetonitrile in a sealed tube. The tube 
was degassed again and heated at 70 °C for 2 h.  The reaction mixture was cooled and filtered through 
a celite bed. The filtrate was concentrated in vacuum and the residue purified through silica gel (60-
120 mesh) column chromatography using petroleum ether to generate a 3-Trifluoromethyl-5-
trimethylsilanylethynyl-benzoic acid methyl ester (14 g, yield 66 %) as yellow liquid. 
Step 2.  Potassium carbonate (0.58 g 4.2 mmol) was added to a solution of 3-Trifluoromethyl-5-
trimethylsilanylethynyl-benzoic acid 2-methyl ester (14.0 g, 46.60 mmol) in 50 mL methanol and 
stirred at room temperature for 20 minutes. The reaction mixture was concentrated under reduced 
pressure.  The residue was diluted with 100 mL ethyl acetate, washed with water and brine and dried 
over anhydrous sodium sulphate and concentrated to yield 3-Ethynyl-5-trifluoromethyl-benzoic acid 
methyl ester (11 g, yield 61%) as a brown liquid. 
Step 3. Lithium hydroxide (6.0 g, 144.10 mmol) was added to an ice cooled solution of 3-Ethynyl-5-
trifluoromethyl-benzoic acid methyl ester (11.0 g, 48.03 mmol) in 50 mL tetrahydrofuran and 25 mL 
water and stirred at room temperature for 3 h. The reaction mixture was concentrated and acidified 
with aqueous citric acid solution. The precipitated solid was filtered, washed with water and dried to 
generate 3-Ethynyl-5-trifluoromethyl-benzoic acid (9.2 g, yield 78%) as pale brown solid. 
Step 4. Dicyclohexylcarbodiimide (13.28 g, 64.48 mmol) and pentafluorophenol (11.8 g, 64.48 
mmol) in 50 mL tetrahydrofuran was added to a solution of 3-Ethynyl-5-trifluoromethyl-benzoic acid 
(9.2 g, 42.99 mmol) and stirred at room temperature for 3 h. Upon the completion of the reaction, the 
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mixture was cooled in an ice bath and the precipitated dicyclohexylurea removed by filtration. The 
filtrate was concentrated and purified using a silica gel (60-120 mesh) column chromatography using 
ethyl acetate in petroleum ether, producing 3-Ethynyl-5-trifluoromethyl-benzoic acid 
pentafluorophenyl ester (13.6 g, yield 83%) as an off-white solid. 
Step 5.  Monobocguanidine (6.82 g, 42.94 mmol) was added to a solution of 3-Ethynyl-5-
trifluoromethyl-benzoic acid pentafluorophenyl ester (13.6 g, 35.78 mmol) in 50 mL tetrahydrofuran 
and stirred at room temperature for 4 h. After the completion of the reaction, the mixture was 
evaporated and purified through silica gel (60-120 mesh) column chromatography using ethyl acetate 
in petroleum ether to generate tert-butylN-[N-[3-ethynyl-5-(trifluoromethyl)benzoyl] carbami-
midoyl]carbamate (8.2 g, yield 64 %) as an off white solid. 
Step 6:  10 mL of concentrated H2SO4 was added dropwise to a solution of 5-bromo-2-iodobenzoic 
acid (100 g, 305.89 mmol) in 800 mL MeOH. The mixture was refluxed for 16 h and then 
concentrated. The residue was dissolved in 1 L ethyl acetate. The organic layer was washed with 
saturated NaHCO3 and 3 ´ 200 mL brine, dried over Na2SO4, filtered and concentrated to generate 5-
Bromo-2-iodo-benzoic acid methyl ester (101.4 g, yield 90%) as yellow solid.  
Step 7. Copper (I) bromide (1.21g, 8.45 mmol) was added to a solution of 5-Bromo-2-iodo-benzoic 
acid methyl ester (24 g, 70.4 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (13.5 mL, 
105.6 mmol) in 80 mL N-methyl-2-pyrrolidinone. The reaction mixture was stirred at 100 °C for 5 h. 
The reaction was filtered and partitioned between ethyl acetate and brine. The aqueous layer was 
extracted with ethyl acetate, and the organic layers were combined and dried over Na2SO4. After 
filtration, the solvent was removed in vacuo. The residue was purified by silica gel column (0-4% 
Ethyl acetate in Petroleum ether) to give the 5-Bromo-2-trifluoromethyl-benzoic acid methyl ester 
(119.2 g, yield 96%) as yellow oil.  
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Step 8.  Lithium hydroxide (4.4 g, 104.76 mmol) was added to an ice cooled solution of 5-Bromo-2-
trifluoromethyl-benzoic acid methyl ester (9.1 g, 35.68 mmol) in 20 mL tetrahydrofuran and 10 mL 
water and stirred at room temperature for 3 h.  The reaction mixture was concentrated and acidified 
with aqueous citric acid solution. The precipitated solid was filtered, washed with water and dried to 
produce 5-Bromo-2-trifluoromethyl-benzoic acid (8 g, yield 95%) as pale yellow solid. 
Step 9. 5-Bromo-2-trifluoromethyl-benzoic acid (8.0 g, 29.74 mmol) in 40 mL thionyl chloride 
solution was heated to reflux for 3 h. The completion of reaction (conversion of acid chloride to 
methyl ester) was observed by thin layer chromatography (TLC). Thionyl chloride was evaporated 
and the residue added to the reaction mixture containing 2-amino pyridine (3.2 g, 32.71 mmol), 
triethyl amine (12.44 mL, 89.21 mmol) in dry 80 mL ethyl acetate at 0 ºC.  The reaction mixture was 
stirred at room temperature for 12h. Reaction completion was observed by TLC.  The reaction mixture 
was then added to 200 mL water and extracted with 2 ´ 200 mL ethyl acetate. The combined organic 
layer was washed with 2 ´ 100 mL water, brine, dried over sodium sulphate and evaporated. The 
crude material was purified by column chromatography using ethyl acetate in petroleum ether to 
generate 5-Bromo-N-pyridin-2-yl-2-trifluoromethyl-benzamide (5.1 g, yield 49%) as off white solid. 
Step 10. 5-Bromo-N-pyridin-2-yl-2-trifluoromethyl-benzamide intermediate (0.690 kg, 2 mol.), CuI 
(0.019 kg, 0.1 mol.), Pd(PPh3)2Cl2 (0.140 kg, 0.2 mol.) and acetonitrile  were mixed in a 6 L reactor 
under nitrogen. Tert-butyl N-[N-[3-ethynyl-5-(trifluoromethyl)benzoyl]carbamimidoyl]carbamate 
intermediate (0.924 kg, 2.6 mol) was added in 5 min on the suspension while stirring at 25 °C. The 
mixture was degassed under nitrogen bubbling for an additional 30 min while still stirring. 
Triethylamine (0.605 kg, 5.98 mol) was added in 17 min at 25 °C. An exotherm of  + 6 °C was 
observed. The dropping funnel was washed with 0.5 L acetonitrile. The reaction mixture was heated 
at 45 °C and maintained for 2 h until tert-butyl N-[N-[3-ethynyl-5-(trifluoromethyl)benzoyl]-
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carbamimidoyl]carbamate was < 1%. The suspension was then cooled to 10 °C at the rate of – 20 
°C/h and maintained for 1 h. The expected intermediate tert-butyl N-[N-[3-[2-[3-(2-pyridyl-
carbamoyl)-4-(trifluoromethyl)phenyl]ethynyl]-5-(trifluoromethyl)benzoyl]-carba-mimidoyl] 
carbamate was filtered and the cake was washed with 1.4 L acetonitrile followed by 0.7 L water. 
After drying by nitrogen flux overnight at 0.3 bar, tert-butyl N-[N-[3-[2-[3-(2-pyridylcarbamoyl)-4-
(trifluoromethyl)phenyl]ethynyl]-5-(trifluoromethyl)benzoyl]carbamimidoyl]-carbamate was 
isolated (0.745 kg, yield 60%). 
Step 11. A suspension of tert-butyl N-[N-[3-[2-[3-(2-pyridylcarbamoyl)-4-(trifluoromethyl) phenyl]-
ethynyl]-5-trifluoromethyl)benzoyl]carbamimidoyl]carbamate (1.5 kg, 2.42 mol)  in 14.5 L  ethyl 
acetate  was heated at 70 °C while stirring. Trifluoroacetic acid (2.2 kg, 19.30 mol) was added in 30 
min at 70 °C. The dropping funnel was washed with 0.75 L ethyl. The reaction mixture was 
maintained for 22 h at 70 °C until tert-butyl N-[N-[3-[2-[3-(2-pyridylcarbamoyl)-4-(trifluoromethyl)-
phenyl]ethynyl]-5-(trifluoromethyl)benzoyl]carbamimidoyl]carbamate was < 1%. After cooling at 
20 °C the mixture was basified by addition of a solution of 28% NH4OH in 1 h until pH was between 
9-10. After an additional 15 min stirring, 11.3 L water were added and the phases separated. The 
organic layer was diluted with 45 L, 30 vol ethyl acetate and washed successively with an aqueous 
solution of sodium metabisulfite (Na2S2O5 0.15 kg in 15 L water) and 15 L water. An additional 
treatment with charcoal (Darco S51) was done. 56.37 kg of ethyl acetate solution was used for the 
next salification step. 
Step 12. A part of the previous acetate solution of 5-((3-(carbamimidoylcarbamoyl)-5-(trifluoro-
methyl)phenyl)ethynyl)-N-(pyridin-2-yl)-2-(trifluoromethyl)benzamide (0.958 kg, 1.844 mol,), 
which was estimated to be pure, was concentrated under a reduced pressure of 100 mbars and at 50 
°C into 10 vol of ethyl acetate. An additional azeotropic drying was realized with 15 vol ethyl acetate. 
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The obtained 10 vol solution was heated at 50 °C, and then a seeding with 2% of 5-((3-
(carbamimidoylcarbamoyl)-5-(trifluoromethyl)phenyl)ethynyl)-N-(pyridin-2-yl)-2-(trifluorom-
ethyl)-benzamide malonic acid  was done. A solution of malonic acid (0.192 kg, 1.144 mol.) in 2.8 L 
ethyl acetate was added in 30 min at 50 °C. The dropping funnel was washed with 0.4 L ethyl acetate 
and crystallization was observed during the addition of the acid. Stirring was maintained for 1 h at 50 
°C and cooled to 10 °C at the rate of -20 °C/h. 5-((3-(carbamimidoylcarbamoyl)-5-(trifluoromethyl) 
phenyl)ethynyl)-N-(pyridin-2-yl)-2-(trifluoromethyl) benzamide malonic acid was isolated by a fast 
filtration and the cake was washed twice with 1 L ethyl acetate. The product was dried under nitrogen 
flux overnight to generate 5-((3-(carbamimidoylcarbamoyl)-5-(trifluoromethyl) phenyl)ethynyl)-N-
(pyridin-2-yl)-2-(trifluoromethyl)benzamide malonic acid compound (1.096 kg,  yield of 95.3%). 
 
Nuclear magnetic resonance (NMR) and mass spectrometry (MS) analysis 
1H NMR and 13C NMR data were recorded on a Bruker 400MHz AVANCE series or Bruker300 MHz 
DPX Spectrometer with CDCl3 or DMSO-d6 or CD3OD as solvent. 1H chemical shifts were 
referenced at 7.26 ppm for CDCl3, 2.5 ppm for DMSO-d6 and 3.3 ppm for CD3OD. 13C chemical 
shifts were referenced at 77 ppm for CDCl3, 39 ppm for DMSO-d6 and 44 ppm for CD3OD, and 
obtained with 1H decoupling. Multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet 
(t), quartet (q), doublet-doublet (dd), quintet (quint), sextet (sextet), septet (septet), multiplet (m), and 
broad (br). 
 
MS data were measured on Agilent 1200/1260 Series LC/MSD mass spectrometer with the following 
settings. Column: Zorbax XDB C18 (50 X 4.6) mm, 5µm or Acquity BEH C18 (50 x 2,1 mm; 1.7 
µm). Mobile phase: Solvent A: 0.1% Formic Acid in Milli-Q water (or) 0.1% Trifluoroacetic acid in 
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Milli-Q-water. Solvent B: Acetonitrile. Flow rate: 1.5 mL/min. Injection Volume: 2 µL. Wavelength: 
Maximum chromatogram (210-400nm). Run time: 6.0 min.  Ionization source: Multi-mode (ESI and 
APCI). Purity was measured on an Agilent 1200/1260 Series HPLC spectrometer. Column: C18 (250 
X 4.6) mm, 5µm (or) C18 (150 X 4.6) mm, 5µm. Mobile phase: Solvent A: 10 mM ammonium acetate 
in Milli-Q water (or) 0.1% Trifluoroacetic acid in Milli-Q-water; Solvent B: Acetonitrile. Flow rate: 
1.0mL/min. Injection Volume: 2 µL. Wavelength: Maximum chromatogram (210-400 nm). Run time: 
30 min.    
 
For compound 1c, MS data were measured with UPLC-SQD (Simple Quad, from Waters). Column: 
Acquity BEH C18 (50 x 2,1 mm; 1.7 µm). Mobile phase: Solvent A: H2O+0.05% TFA; Solvent B: 
CH3CN+0.035% TFA. Flow rate; 1 mL/min. UV Detection: l = 220 nm. MS detection (Simple Quad) 
ionization: ESI + Electrospray First / Last Mass (uma) FS: 160 / 1200 uma. Capillary voltage (KV): 
3.5.Cone. (V): 20. Source Temperature: 150°C. Desolvation temperature: 500°C. Desolvation gas 
flow (L/hr): 1200. Cone gas flow (L/hr): 100. LM 1 resolution: 13.00. HM1 resolution: 13.00. Ion 
energy1: 0.20.  
For the intermediate 5-Bromo-2-iodo-benzoic acid methyl ester (step 6), LC-MS was measured as 
follows: Column: XBridge C18,4.6*50mm, 3.5 µm Mobile phase: 10 mM NH4HCO3 (A) / 
acetonitrile (B). Elution program: Gradient from 5 to 95% of B in 1.6 min at 1.8 mL/min. 
Temperature: 50ºC. Detection: UV (214, 4 nm). MS: ESI, Positve mode, 110 to 1000 amu. 
 
Determination of  ex vivo potency against P. falciparum and P. vivax  
Compounds. MMV688533 (Sanofi, Toulouse, France) and the reference antimalarial drugs 
chloroquine, piperaquine, mefloquine, and artesunate (provided by the WWARN QA/QC Reference 
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Material Programme), were prepared as 1 mg/mL stock solutions in dimethyl sulfoxide (DMSO) or 
H2O according to the manufacturers’ instructions. Drug plates were pre-dosed by diluting the 
compounds in 50% methanol followed by lyophilization and storage at 4 °C. 
 
Field location and sample collection. In Papua Indonesia, Plasmodium isolates were collected from 
patients attending malaria clinics in Timika, a region endemic for multidrug-resistant strains of P. 
vivax and P. falciparum (39, 40). Patients with symptomatic malaria were recruited into the study if 
singly infected with P. falciparum or P. vivax, with a parasitemia of between 2,000 and 80,000 
parasites per μL, and a majority (>60%) of parasites present as rings. Venous blood (5 mL) was 
collected by venipuncture and host white blood cells were removed with Plasmodipur filters 
(EuroProxima B.V., The Netherlands). Packed infected RBCs were then used for ex vivo drug 
susceptibility assays. In Uganda, Plasmodium isolates were collected from patients aged 6 months 
or older presenting to the Tororo District Hospital, Tororo District, or Masafu Hospital in the Busia 
District, with a clinical syndrome suggestive of malaria and Plasmodium falciparum parasites 
identified in blood by microscopy. Informed consent was obtained from patients and/or primary care 
givers (depending on age). 
 
Ex vivo drug susceptibility assays. In Papua Indonesia, drug susceptibility was measured in P. vivax 
and P. falciparum isolates using a protocol modified from the WHO microtest (40-42). In brief, 200 
μL of a 2% hematocrit of blood media mixture, consisting of RPMI 1640 medium plus 10% AB+ 
human serum for P. falciparum or McCoy’s 5A medium plus 20% AB+ human serum for P. vivax 
was added to each well of pre-dosed drug plates containing 11 serial concentrations (2-fold dilutions) 
of the test antimalarials (maximum concentration shown in brackets) chloroquine (2,993 nM), 
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piperaquine (1,029 nM), mefloquine (338 nM), artesunate (49 nM), and MMV688533 (237 nM). A 
candle jar was used to mature the parasites at 37 °C for 35-56 h. Incubations were stopped when 
>40% of the ring-stage parasites had reached the mature schizont stage in the drug-free control wells, 
as determined by light microscopy. Parasite growth was quantified by nucleic acid staining and 
parasitemias were measured using flow cytometry. Parasite growth was quantified for each drug 
concentration and normalized to the control well. The dose-response data were analyzed using 
nonlinear regression analysis and the half-maximal inhibition of growth (IC50) values derived using 
an inhibitory sigmoid Emax model (In vitro Analysis and Reporting Tool; IVART7). Ex vivo IC50 
data were only used from predicted curves where the Emax and E0 were within 15% of 100 and 1, 
respectively. The drug plate quality was assured by running schizont maturation assays with the P. 
falciparum chloroquine-resistant strain K1 and the chloroquine-sensitive strain FC27. For data 
quality control, raw flow cytometry values were analyzed by two independent operators and 
compared. If the raw dose-response data derived by the two operators led to a dramatic shift in IC50 
estimates for any of the drugs, they were reviewed and adjusted by a third operator. Ethical approval 
for this study was obtained from the Eijkman Institute Research Ethics Commission of the Eijkman 
Institute for Molecular Biology, Jakarta, Indonesia; the Human Research Ethics Committee of the 
Northern Territory Department of Health & Families; and the Menzies School of Health Research, 
Darwin, Australia. 
 
In Africa, drug susceptibility was measured in P. vivax and P. falciparum isolates using a protocol 
summarized as follows: All MMV compounds were dissolved in DMSO to a final concentration 
of 0.5-10 mM and stored at -20°C. On the day of assay, 2 µL of DMSO stocks drug were diluted 
in 498 µL complete RPMI media (RPMI 1640 medium supplemented with 25 mM HEPES, 0.2% 
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NaHCO3, 0.1 mM hypoxanthine, 100 µg/mL gentamicin, and 0.5% Albumax I [Invitrogen]). 
Diluted drugs were not stored for longer than 24 h. Drugs were serially diluted 3-fold in 96-well 
assay plates in complete media containing 0.4% DMSO, to a final volume of 50 µL, in columns 
1-10. Column 11 contained drug-free controls while column 12 contained uninfected RBC 
controls. Parasitized whole blood samples were washed 3 times with RPMI (w/o Albumax) media 
at 37 °C and then resuspended in fresh RPMI media to a final hematocrit of 2%. 150 µL of the 
parasite culture was added to each well into the assay plate for final parameters of 0.2% parasitemia 
and 2% hematocrit. Plates were incubated for 72 h in a humidified modular incubator under a tri-
gas mixture (5% O2, 5% CO2, 90% N2) at 37 °C. Plates were then stained with SYBR Green I and 
fluorescence determined using a BMG Fluostar Optima plate reader at excitation 485 nm / 
emission 530 nm (43). Fluorescence data were curve fitted to estimate IC50 values (GraphPad 
Prism 7). For each isolate, a Z’ factor was calculated from drug-free positive and negative controls 
(8 parasitized RBC wells and 8 uninfected RBC wells, respectively). 
 
Determination of efficacy and pharmacokinetic profiles in the Pf SCID mouse model  
Immunodeficient female NSG or NOG mice were engrafted with a minimum of 40% human 
erythrocytes circulating in peripheral blood during the entire experiment. Each mouse was inoculated 
with a 50%-75% hematocrit erythrocyte suspension (Basque Center of Transfusion and Human 
Tissues, Galdakao, Spain and Bank of Blood and Tissues, Barcelona, Spain) in RPMI1640 medium, 
25% (vol/vol) decomplemented human serum, 3.1 mM hypoxanthine. Intraperitoneal (i.p.) and/or 
intravenous (i.v., via tail lateral vein) injections were done once daily until the end of the drug 
administration period. Humanized NSG or NOG mice were infected with peripheral blood from CO2-
euthanized donor mice harboring 5-10% parasitemia. The humanized mice of the efficacy study were 
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infected by inoculation of 0.3 mL of the infected-erythrocyte suspension by the lateral vein of the 
tail. For treatment, drug was administered at Day 1 (~1% patent parasitemia) (P0) by oral gavage 
(volume p.o. is 10 mL/kg body weight). To measure the therapeutic response, 2 μL peripheral tail 
blood from P. falciparum-infected mice were stained with TER-119-Phycoerythrine (marker of 
murine erythrocytes) and SYTO-16 (nucleic acid dye) and analyzed by flow cytometry (Attune NxT 
Acoustic Focusing Flow Cytometer, Invitrogen). Drug effect on circulating P. falciparum 
Pf3D70087/N9 parasites was assessed by microscopy (Giemsa-stained blood smears; 2 μL blood 
samples taken at 48 h and 96 h).  
 
To assess the drug concentrations in mice, 25 μL samples of peripheral blood were taken at different 
times (usually 0.5, 1, 2, 4, 6 or 8 h and 23 h after the first dosing), mixed with 25 μL of MilliQ H2O 
and immediately frozen on a thermal block at -80º C. The treated mice that reached the limit of 
detection by standard flow cytometry (<0.01% from total circulating erythrocytes) were maintained 
until day 60 of the assay with a chimerism >50% of total circulating erythrocytes by regular injection 
of human erythrocytes every 3 or 4 days. During the follow up period, 2 μL blood samples were 
taken every 2 or 3 days and analyzed by flow cytometry with a limit of quantification of 0.1%. The 
first day of parasitemia detection was recorded. The mice were deemed cured (free of detectable 
parasite) if no recrudescence was detected by day 60. 
 
As biological controls; a) parasite growth in untreated and/or vehicle-treated individuals was 
evaluated from day 1 to 5; b) the parasite burden was measured from day 1 to 5 of the assay in 
individuals treated with a fixed dose of a standard antimalarial; and c) the distribution of parasitemia 
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at day 1 of the assay for all individual mice tested in the assay was compared to parasitemia 
distributions in previous experiments. 
 
For data analysis, ED90 and AUCED90 were defined and calculated according to (14). ED90 is the 
effective dose in mg/kg that reduced parasitemia by 90% at day 5 compared to vehicle-treated mice. 
AUCED90 is the average estimated daily exposure that reduced parasitemia from peripheral blood at 
day 5 of the assay by 90% compared to vehicle-treated mice. The ED90 was calculated by fitting the 
variable Y= log10 [parasitemia at day 5 of the assay] and the variable X= log10 [dose level in mg/kg] 
defined as an ordered pair for every individual of the study. The AUCED90 was calculated by fitting 
the variable Y= log10 [parasitemia at day 5 of the assay] and the variable X= log10 [AUC of compound 
during the first 23 h after the first drug administration, in ng·h/mL] defined as an ordered pair for 
every individual of the study. The equation used to fit the data is Y=Bottom + (Top-
Bottom)/(1+10((LogED50-X)×Hill Slope)). The ED90 and AUCED90 were calculated by interpolation 
of the X value that corresponded to antilog10 [Y= “Top”-1] in each respective best fitted curve (14).  
 
The time in days (te) and the average concentration in blood (C, in ng/mL) for killing all P. 
falciparum parasites in mice were interpolated from a multivariate logistic regression. The fitted 
function links the dichotomic response variable Therapeutic response (Tr), which takes Tri=0 if an 
individual shows recrudescence and Tri=1 if no recrudescence was detected at day 60 of the assay, 
and the explanatory variables te and C. These parameters offered direct empirical estimates of the 
time of exposure and concentration in blood to at least kill a defined number of circulating parasites, 




Data analysis was performed using GraphPad Prism 7.0 (GraphPad Software), Excel 2016 
(Microsoft) and R free software (https://www.r-project.org). Phoenix WinNonlin vers.7.0 
(Certara) was used for PK Non-Compartmental Analysis. Animal experiments performed at TAD 
were approved by The Art of Discovery Institutional Animal Care and Use Committee (TAD-
IACUC). The Committee is certified by the Biscay County Government (Bizkaiko Foru Aldundia, 
Basque Country, Spain) to evaluate animal research projects from Spanish institutions according 
to point 43.3 from Royal Decree 53/2013, from the 1st of February (BOE-A-2013-1337). All 
experiments were carried out in accordance with European Directive 2010/63/EU. The results from 
the animal experiments are reported following ARRIVE guidelines. 
(https://www.nc3rs.org.uk/arrive-guidelines) except for disclosure of business trade confidential 
information. 
 
Prediction of the efficacious dose in humans based on Pf SCID mouse PK/PD  
The prediction of the first efficacious dose in human was based on: 1) minimum parasiticidal 
concentration (MPC) as evaluated from a population-based PK/PD modeling of experimental data 
from SCID mouse studies. At team at MMV used a NonMem software and another at Sanofi used 
a Monolix software to build a PK/PD model. Both teams reached a similar median estimate value 
of 20 ng/mL as the MPC; 2) Kkill of the compound as deduced from in vitro logPRR (5 in 48 h). 
However, a conservative approach was recommended by MMV to use a capped value of 3 based 
on values observed for endoperoxides when tested in human; 3) predicted human PK parameters 
as determined by an allometric approach. For the allometric scaling of clearance from animal data, 
two methods, Mahmood rules and Fixed exponent method, were used. These led to the prediction 
of a low to a very low MMV688533 clearance in humans 3.6 and 1.4 L/h respectively, that 
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corresponded to a total clearance of < 5% of hepatic blood flow. This in turn corresponded to a 
predicted half-life of 103 h and 277 h respectively in humans. The volume of distribution (Vdss) 
relying on allometry method with an exponent of 1, was predicted to be as large as 540 L for 70 
kg human; 4) biopharmaceutical model (GastroPlus) used to estimate Fa% vs dose in human and 
verified on Rat & Dog PK data. 
 
P. falciparum lines used for selections, drug assays and transfections  
Asexual blood-stage parasites were cultured at 3% hematocrit in O+ human erythrocytes in RPMI-
1640 medium supplemented with 50 μM hypoxanthine, 2.25 g/L NaHCO3, 2 mM L-glutamine, 25 
mM HEPES, 0.5% (w/v) AlbuMAXII (Invitrogen) and 10 μg/mL gentamycin at 37 °C in flasks 
gassed with 5% O2/5% CO2/90% N2. The P. falciparum 3D7-A10 and Dd2-B2 clones used for the 
selections and drug assays, and the NF54attB line used to express pfacg1-eGFP and pfehd-3´HA, 
have been previously reported (15, 44, 45).  
 
Genome editing  
Mutations in PfACG1 and PfEHD that were identified from the in vitro selections were validated 
by engineering them into the parental 3D7-A10 line using an “all-in-one” pDC2-based 
CRISPR/Cas9 plasmid ((46); Fig. S2A). The Cas9 in this plasmid is derived from Streptococcus 
pyogenes, has been codon optimized for P. falciparum, and is under the expression of a calmodulin 
promoter. The plasmid also contains a human dhfr (hdhfr) selectable marker (that confers 
resistance to WR99210) under a PcDT promoter, and the sequence encoding the guide RNA 
(gRNA) under a U6 promoter. Guide RNAs were selected using the online tool ChopChop based 
on their proximity to the mutation of interest, GC content, and absence of poly A/T tracks 
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(http://chopchop.cbu.uib.no). The gRNA primers were annealed with BbsI overhangs using PCR 
and cloned into a BbsI-linearized pDC2 CRISPR/Cas9 vector. The donor templates, also supplied 
on the same plasmid, had >300bp of homology flanking the mutation of interest. These fragments 
were first amplified by PCR and cloned into pGEM-T vectors to introduce shield mutations by 
site-directed mutagenesis. Shielded donor fragments were then amplified by PCR and cloned into 
the EcoRI/AatII-linearized pDC2 CRISPR/Cas9 vector by In-Fusion cloning (Takara). Finally, the 
plasmids were midi-prepped for transfections. 
 
Parasites were electroporated with purified circular plasmid DNA as described (47). Briefly, a 2.5 
mL culture of 3D7-A10 or sel. 533-CL1 (³ 5% rings) was washed and resuspended in 220 µL 1´ 
Cytomix. This mixture was then added to 50 μg of plasmid DNA and electroporated at a voltage 
of 0.31 kV and capacitance of 950 µF inside 2 mm gap cuvettes (Bio-Rad) using a Gene-Pulser 
(Bio-Rad) (48). Starting one day after the transfections, the cultures were selected for six days with 
2.5 nM WR99210 (49) and maintained thereafter in complete media until recrudescence. Gene 
editing was assessed via Sanger sequencing of blood PCR (Bioline) from bulk cultures. Edited 
parasite clones were obtained by limiting dilution. The parasites were then assayed for resistance 
to MMV688533 using flow cytometry.  
 
Both the mycobacteriophage Bxb1 serine integrase system (48) and CRISPR/Cas9 gene editing 
tools were used to generate the doubly-tagged parasite line expressing PfACG1-eGFP and PfEHD-
3´HA fusion proteins. Briefly, NF54attB parasites (45) were first co-transfected with an integrase-
expressing plasmid pINT and a donor attP-containing plasmid pDC2-pfacg1-eGFP. This donor 
plasmid also contained a blasticidin S-deaminase (BSD) selectable marker that confers resistance 
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to blasticidin hydrochloride (50). The integrase plasmid pINT contained a Neomycin selectable 
marker that confers resistance to geneticin (G418; (51); Fig. S2B). Transfections were done as 
described above and the cultures maintained in 250 µg/mL G418 + 2 µg/mL BSD media for six 
days post-transfection, followed by 2µg/mL BSD media until recrudescence. Sorbitol-
synchronized eGFP-tagged ring-stage clonal parasites obtained by limiting dilution were then 
transfected with the codon-optimized all-in-one plasmid containing a 1.1kb pfehd donor fragment 
consisting of two 3’ homology sequences flanking the 3´HA tag (Fig. S2C). These transfections 
were selected with 2.5 nM WR99210 until recrudescence. Successful gene tagging was confirmed 
via PCR, Sanger sequencing and immunofluorescence assays. 
  
Conditional knock-down (cKD) parasite studies 
Generation of cKD parasite lines. To investigate the interaction between MMV688533 and 
PfACG1 and PfEHD genes, we utilized CRISPR/Cas9 to generate parasite cell lines stably 
expressing the TetR-DOZI-RNA aptamer module for conditional regulation of target gene 
expression. These transgenic lines also contained the reporter construct Renilla luciferase (RLuc), 
the selection marker Blasticidin-S deaminase, and a C-terminal 2´HA epitope tag (17). To 
construct the donor plasmids, PCR-amplified right homology regions (RHR) and BioXP3200 
System-synthesized DNA fragments corresponding to the left homology regions (LHR) fused to 
the re-codonized 3'-end of each target genes, as well as the target specifying guide RNA sequences, 
were cloned via Gibson assembly into the pSN054 linear vector (52). The final constructs were 
confirmed by restriction digests and Sanger sequencing. Transfections into Cas9- and T7 RNA 
polymerase-expressing NF54 parasites were carried out by preloading erythrocytes with the donor 
plasmids as described previously (53). Cultures were maintained in 500 nM anhydrotetracycline 
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(aTc; Sigma-Aldrich 37919) and 2.5 µg/mL of Blasticidin-S (RPI Corp B12150-0.1). Parasite cell 
lines stably integrating the donor plasmids were monitored via Giemsa smears and RLuc 
measurements. 
 
Western blotting of cKD parasite lines. PfACG1 and PfEHD cKD parasites were cultured with 
50 nM aTc or without aTc to maintain and downregulated protein expression, respectively. 
Proteins were then extracted after 72 h via saponin lysis and resuspended in lysis buffer that 
consists of 4% SDS and 0.5% Triton X-114 in 1´PBS. Proteins were separated on Mini-
PROTEAN TGX precast gels (4-15% gradient) in tris-glycine buffer, transferred to a 
polyvinylidene fluoride (PVDF) membrane using the Mini Trans-Blot Electrophoretic Transfer 
Cell system, and blocked with 100 mg/mL skim milk in TBS/Tween. Membrane-bound proteins 
were probed with mouse anti-HA (1:3000; Sigma H3663) and rabbit anti-GAPDH (1:5000; Abcam 
AB9485) primary antibodies, and anti-mouse (1:5000; Thermo Fisher Scientific 62-6520) and 
anti-rabbit (1:5000; Cell signaling 7074S) horseradish peroxidase (HRP)-conjugated secondary 
antibodies. Following incubation in SuperSignal West Pico Chemiluminescent substrate (Thermo 
Fisher Scientific PI34080), protein blots were imaged and analyzed using the ChemiDoc MP 
System and Image Lab 5.2.0 (Bio-Rad). 
 
cKD proliferation assays. To assess the effect of conditionally perturbing PfACG1 and PfEHD 
expression on parasite growth, synchronous ring-stage parasites cultured in the presence (50 and 
3 nM) or absence of aTc were cultured in triplicate in a 96-well U-bottom plate (Corning 62406-
121). Luminescence signals were taken at 0, 72, and 120 h post-invasion using the Renilla-Glo(R) 
Luciferase Assay System (Promega E2750) and the GloMax Discover Multimode Microplate 
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Reader (Promega). The luminescence values in the knockdown conditions were normalized to 
aTc-treated (100% growth) and chloroquine-treated (200 nM) samples (no growth) as controls and 
results were analyzed using GraphPad Prism (version 8; GraphPad Software). 
 
Compound susceptibility assays with cKD parasite lines. A stock solution of MMV688533 was 
dispensed into 96-well U-bottom plates and serially diluted in complete medium to yield final 
concentrations ranging from 0.3-160 nM. Synchronous ring-stage PfACG1 and PfEHD cKD 
parasite lines as well as a control cell line expressing an aptamer-regulatable fluorescent protein 
were maintained in the presence (500 nM) or absence of aTc and were distributed into the drug 
plates. DMSO- and chloroquine-treated samples (200 nM) served as reference controls. 
Luminescence was measured after 72 h as described above and EC50 values were obtained from 
corrected dose-response curves using GraphPad Prism. 
 
Immunofluorescence assays 
Indirect IFA studies were performed in suspension. Cells were fixed in 4% (v/v) formaldehyde 
(Thermo Fisher Scientific) for 1 h at room temperature. followed by a second fixation step 
supplementing the 4% formaldehyde solution with 1 mM cysteine and CaCl2 and subsequent 
incubation overnight at 4 °C. Cells were then permeabilized on ice using 0.05% Triton X-100 in 
1´PBS for 5 min. Autofluorescence was quenched using a 50 mM glycine treatment for 10 min. 
After two washes in 1´ PBS the cells were resuspended in 1% (w/v) bovine serum albumin (BSA) 
in 1´PBS blocking buffer and were then incubated with the appropriate dilution for each primary 
antibody used (1:200 for rabbit anti-ERD2 (BEI Recourses), anti-PMT (kindly provided by 
Choukri Ben Mamoun), anti-PDI (mouse anti-PDI (1D3), Enzo Life Sciences), rabbit or mouse 
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anti-GFP (Takara (Clontech), Roche),  rabbit anti-HA antibodies (Sigma), 1:50 for rabbit anti-
Rab5A, Rab5C, or Rab11A, rat anti-Rab5B or Rab7 (kindly provided by Gordon Langsley), 1:200 
for anti-coronin (kindly provided by Jake Baum), 1:200 for anti-ACP (kindly provided by Geoffrey 
McFadden), 1:200 for anti-K13 (22), 1:200 for anti-PfCRT antibodies (54) followed by incubation 
with corresponding species-specific secondary antibodies (Alexa Fluor 488-, 594- or 647- 
conjugated goat anti mouse or rabbit antibodies; Thermo Fisher) diluted 1:2000 in 1% BSA in 1´ 
PBS. MitoTracker Red CMXRos (Thermo Fisher) was used to stain mitochondria. HCS LipidTOX 
Deep Red Neutral Lipid Stain and Nile Red (Invitrogen) were used to stain neutral lipid bodies 
according to the protocol provided by the manufacturer. Thin blood smears of stained RBCs were 
prepared on microscope slides and mounted with cover slips using Prolong Diamond Antifade 
Mountant with DAPI (Thermo Fisher). Parasites were imaged using a Nikon Eclipse Ti-E wide-
field microscope equipped with a sCMOS camera (Andor) and a Plan-apochromate oil immersion 
objective with 100× magnification (1.4 numerical aperture). A minimum of 27 Z stacks (0.2 μm 
step size) were photographed for each parasitized RBC. NIS-Elements imaging software (Version 
5.02, Nikon) was used to control the microscope and camera as well as to deconvolve the images 
(using 25 iterations of the Richardson-Lucy algorithm for each image) and perform 3D 
reconstructions (22). ImageJ (Fiji) (version 2.0.0-rc-68/1.52 h) was used to crop the images, adjust 
brightness and intensity, overlay channels and prepare montages. 
 
Evaluation of genotoxicity 
Salmonella typhimurium test strains including the mixed strains TA7001 and TA7006 for detection 
of base-pair substitutions and TA98 strain for detection of frameshift mutations were used for 
genotoxicity testing (Ames test). MMV688533 was cytotoxic starting at 300 µg/mL in mixed and 
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TA98 strains in the absence of metabolic activation. Cytotoxicity was also noted in the presence of 
metabolic activation starting from 100 µg/mL in TA98 strain and from 1000 µg/mL in mixed strains. 
Under the conditions of the test, MMV688533 was classified as non-mutagenic. 
 
L5178Y and TK6 cells were used for in vitro micronucleus test to investigate the 
clastogenicity/aneugenicity potential of MMV688533. There was no statistically significant 
increase in the number of micronuclei as compared to the solvent control with or without metabolic 
activation. MMV688533 was therefore deemed non-clastogenic/aneugenic. 
 
Pharmacokinetic studies in mice, rats and dogs 
Pharmacokinetic studies in mice were performed following a single intravenous (3 mg/kg) or oral 
(3.5, 10 and 30 mg/kg) administration of MMV688533 to male Swiss mice (3 dosed intravenous 
(i.v.) and 3 per os (p.o.)). Feeding was performed ad libitum. Vehicles / Formulations were at 0.6 
mg/mL in PEG200/Solutol/G5% (20%/5%/75%) for i.v. solution and at 0.3, 1 and 3 mg/mL in 
Methylcellulose /Tween 80 (0.6%/0.5%) for p.o. suspensions in water. Administration modes were 
i.v. 3 mg/kg, 5 mL/kg and p.o. 3.5, 10 and 30 mg/kg,10 mL/kg. Matrix and Sampling times were 
for i.v. plasma and lung / 0.083, 0.5, 1, 2, 4, 6, 8 and 24 h and for p.o plasma (only at 10 mg/kg), 
blood, liver and lung / 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h. The analytical method was LC-MS/MS with 
a lower limit(s) of quantification 2 ng/mL for plasma, 5 ng/mL for blood and 6 ng/g for tissues. 
PK analysis were performed using non-compartmental models (Plasma, IV bolus and Plasma, 




In rats, the PK studies were performed following a single intravenous (3 mg/kg) or oral (10 mg/kg) 
administration to male Sprague-Dawley rats. The procedure was as described above but for the 
following exception: The rats were not fasted and the oral volume of administration of 10 mg/kg 
was 10 mL/kg Matrix. The sampling times for i.v. blood were 0.083, 0.25, 0.5, 1, 2, 4, 7, 24 and 
48 h and for p.o. blood 0.5, 1, 2, 4, 7, 24 and 48 h. PK analysis was performed using a the 200-
202, IV bolus and Extravascular non-compartmental models. 
 
In dogs, the PK of MMV688533 was performed following a single 2 mg/kg intravenous 
administration of the compound to female Beagle dogs that were fasted overnight. The vehicle / 
formulation solution was at 2 mg/mL PEG400/Ethanol/Solutol HS15/G5 % (20/5/5/70) pH 3. For 
administration, i.v. was the preferred route (2 mg/kg, 1 mL/kg). Matrix and sampling times were 
blood at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 24, 30, 48 and 72 h. The limit of quantification was 1 ng/mL. 
MMV688533 following a single oral dose of 0.5 mg/kg was also administered as malonate salt in 
a capsule or oral solution to male Beagle pentagastrin-dogs weighing 8.6 to 10.8 kg. 3 males per 
dose were dosed p.o, and serial sampling was applied. Feeding conditions were fasted overnight 
and fed 4 h post dosing. Vehicles / Formulations were capsule (MMV688533/microcrystalline 
cellulose/ croscarmellose sodium (5/91.67/3.33) followed by 50 mL of water. Solution at 0.25 
mg/mL in PEG400/Ethanol/Solutol/G5% (20/5/7.5/67.5). Administration mode was p.o. 0.5 
mg/kg (active compound), 2 mL/kg for solution. Matrix and sampling times were blood at 0.25, 





Safety pharmacology profiling 
Preliminary non-clinical toxicology studies in rats. Two-week toxicity studies in rats were 
conducted to evaluate the potential toxicity of MMV688533 (malonate form) when administered 
once daily for 15 days to Sprague Dawley rats by the oral route (gavage). Four study groups, each 
composed of 5 male and 5 female Sprague Dawley rats, were given MMV688533 at 12.5, 25 or 50 
mg/kg/day or vehicle alone [0.5% (w/w) Polysorbate 80 and 0.6% (w/w) methylcellulose in water], 
once daily for 15 consecutive days, under a dose-volume of 5 mL/kg. In addition, 3 satellite 
rats/sex/group were included in the study. These rats received the test item in the same conditions as 
principal animals and were used for toxicokinetic studies. Parameters evaluated included mortality, 
clinical signs, body weight, and food consumption. Blood samples for hematology, coagulation and 
clinical chemistry were collected from all principal animals on day 3 and at necropsy. Blood samples 
for toxicokinetic determinations were obtained from satellite animals at 1, 2, 4, 7 and 24 h after 
dosing on day 1, as well as 1, 2, 4, 7, 24, 48 and 96 h after dosing on day 14. Control animals were 
sampled at 4 and 24 h after dosing on both days. At necropsy, all study animals were observed for 
any macroscopic post-mortem examinations, and weights of selected organs were recorded. 
Representative tissue samples at 50 mg/kg/day and in controls were histologically examined. Tissues 
with suspected compound-related microscopic findings were also evaluated microscopically for rats 
in the lower dose groups. 
 
Preliminary non-clinical toxicology studies in dogs. Two male and two female beagle dogs were 
given MMV688533 (malonate form) at 10, 30 or 100 mg/kg/day, or the vehicle alone [0.5% (w/w) 
Polysorbate 80 and 0.6% (w/w) methylcellulose in water], once a day for 15 consecutive days, under 
a dose-volume of 5 mL/kg. Animals of all groups were treated for 15 days, except for those at 100 
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mg/kg/day, which were euthanized prematurely after 11 and 10 administrations, respectively for 
males and females, for ethical reasons. Parameters evaluated included mortality, clinical signs, body 
weights and food consumption. Blood samples for hematology, coagulation and clinical chemistry 
analyses were collected once during the pretest period and on Days 3 and 8 (all animals), and on Day 
14 (groups 1, 2 and 3). Urine samples for chemistry analyses were collected once during the pretest 
period (all animals) and on Day 14 (groups 1, 2 and 3). At necropsy [Day 10 (group 4 females) or 
11 (group 4 males), or Day 16 for group 1, 2 and 3 animals], all study animals were observed for any 
macroscopic post-mortem examinations, and weights of selected organs were recorded and 
representative tissue samples were examined. In addition, the toxicokinetic profiles of MMV688533 
and its main metabolite MMV893023 were determined from blood samples collected on Day 1 (all 
animals) and on Day 15 (groups 1, 2 and 3) at 1, 2, 4, 7 and 24 hours post-dosing. For group 4 
animals, blood samples for TK determinations were collected on Day 11 for the males or on Day 10 
for the females, before dosing, and 1 and 2 hours post-dosing. 
 
Ex vivo rabbit Purkinje fibers cardiovascular study. This study was designed to evaluate the cardiac 
cellular electrophysiological effects of MMV688533 on the action potential parameters in isolated 
rabbit Purkinje fibers. MMV688533 was tested at 0.1, 1.4, 4.9 and 6.4 μmol/L corresponding to 0.05, 
0.7, 2.5 and 3.3 μg/mL of active ingredient, respectively. The effects of the active MMV688533 
metabolite RA11263363A on resting membrane potential and action potential parameters recorded 
from isolated rabbit Purkinje fibers (male, New Zealand rabbits; 1.3 to 1.5 kg; 7-10 weeks of age) 
were evaluated through a microelectrode technique. The following parameters were measured: 
resting potential (RP in mV), amplitude (APA in mV), maximal rate of rise of action potential (Vmax 
in V/s) and the action potential duration at 50 and 90% of repolarization (APD50 and APD90 in ms). 
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The fibers were superfused with an oxygenated physiological solution containing 120 mM NaCl; 4 
mM KCl; 1 mM MgCl2; 1.8 mM NaH2PO4; 25 mM NaHCO3; 11 mM glucose; 1.8 mM CaCl2; pH 
= 7.4, at 36±1°C. RA11263363A (592.3 g/mol, salt form and 519.4 g/mol, base form, batch 
CLT.CBN1.039.1) was first dissolved into DMSO to obtain a 12 mM stock solution. This solution 
was further diluted with 100% DMSO to obtain solutions at 4, 1.2 and 0.12 mM. These four solutions 
(0.12, 1.2, 4 and 12 mM) were added into the physiological solution to obtain the appropriate nominal 
concentrations of 0.3, 3, 10 and 30 μM, which corresponded to 0.2, 1.6, 5.2 and 15.6 μg/mL of active 
ingredient respectively. The final concentration of DMSO in the test formulation was kept constant 
at 0.25% (v/v) in the physiological solution. Purkinje fibers (n=3) were first superfused by the 
physiological solution. After a 30-minute control period, test compound was evaluated at increasing 
concentrations sequentially applied, every 30 minutes. For each tested concentration, the fibers were 
stimulated at the basal rate of 1 pulse per second (1 Hz). In addition, stimulation rate was decreased 
from 1 pulse per second (1 Hz) to 1 pulse every 4 seconds (0.25 Hz) for 3 minutes, increased again 
to 1 pulse per second for 1 minute and finally increased to 3 pulses per second (3 Hz) for 2 additional 
minutes (between the 19th and the 25th minute). The low stimulation rate was used to favor the 
occurrence of abnormal electrical events during the repolarization phase of the action potential and 
to facilitate the development of Early After Depolarization’s (EADs). The high stimulation rate was 
used to evaluate the use-dependent sodium channel blockade. After the highest concentration, the 
physiological solution was superfused again to evaluate the reversibility of the drug effect (washout). 
 
In vivo anaesthetized guinea pig cardiovascular study. The purpose of this study was to assess the 
potential effects on cardiovascular parameters of continuous intravenous (IV) administration of 
MMV688533 chlorhydrate to anesthetized guinea pigs, when tested at cumulative doses of 10, 20 
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and 30 mg/kg. Each dose was successively administered as a 15-min infusion/dose. Blood 
concentrations of MMV688533 were also assessed. An aqueous solution of ethanol/solutol/NaCl 
(10% / 5% / 85%, v/v/v) was used for the study. Cardiovascular functions were evaluated by 
measuring hemodynamic parameters like arterial blood pressure (BP) and heart rate (HR), and 
electrocardiographic (ECG) parameters. 
 
Animals were premedicated with buprenorphine (0.05 mg/kg intramuscular) ~30 min prior to 
surgery and anesthesia maintained under isoflurane (2-5%) and constant O2 flux (0.7 – 1.3 mL/min). 
Under deep anesthesia, lidocaine was injected subcutaneously at sites of the tracheotomy and 
insertion of electrocardiogram needles, and a tracheotomy performed to allow mechanical ventilation 
followed by carotid (arterial measurements) and jugular (infusion of control article or test article) 
catheterizations. Administration of Ringer lactate solution (5 mL/ kg intraperitoneal), heated to body 
temperature to compensate for the hydric loss inherent to anesthesia, was performed at the discretion 
of the study director according to major bleeding surgery or signal instability (information 
documented in study records). BP and ECG parameters were recorded in anesthetized guinea pigs 
placed on a heating pad. Systemic BP was recorded using an independent catheter pressure 
transducer (MillarTM equipment) introduced into the carotid artery. The standard ECG (one lead 
derivation among L1 or L2 or L3) was recorded using four subcutaneously-placed needle electrodes 
to provide an optimal separation of T wave from P wave of the next complex. Once satisfactory in 
terms of their quality and stability, the signals were recorded for 15 minutes (corresponding to the 
stability period). Thereafter a set of animals (group T2) received a NaCl infusion (starting at T0 min) 
followed by RA11263363A at cumulative doses of 10, 20 and 30 mg/kg. Each infusion was delivered 




At the end of the recovery period (T75 min) one single arterial blood sample (~0.2 mL) was collected 
from the abdominal artery. A second set of animals (group T1) was infused with the control article 
in the same experimental conditions without the terminal blood sampling. A last set (group T3) was 
dedicated to evaluating pharmacokinetic (PK) parameters in which animals fitted with a jugular 
catheter (for RA11263363A infusion) and a carotid catheter (arterial blood sampling) were treated 
in the same experimental conditions as those described for the group T2. At the end of each 15-min 
period of infusion a blood sample (~0.2 mL) was collected. This was also done during the recovery 
period at 5, 10 and 75 min. Each volume of blood collected was immediately replaced by an 
equivalent volume of Ringer lactate solution. Of note, in group T3, at the end of the recovery period 
(T75 min) arterial blood (~0.2 mL) was sampled and was compared to the corresponding sample in 
group T2. All blood samples (0.2 mL) were collected with sodium heparinate as anticoagulant and 
placed on wet ice immediately after collection. Then all samples were stored at -20°C until analysis. 
Thereafter the animals were euthanized by IV or intra-cardiac overdose of sodium pentobarbital. 
 
Patch Clamp electrophysiological hERG assay 
Cell culture procedure. HEK293 cells were stably transfected with hERG cDNA. Stable 
transfectants were selected by co-expression with the Geneticin (G418)-resistance gene incorporated 
into the expression plasmid. Selection pressure was maintained by including G418 in the culture 
medium. Cells were cultured in Dulbecco’s Modified Eagle Medium / Nutrient Mixture F-12 (D-
MEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G sodium, 100 μg/mL 




Electrophysiological Procedures. Cells were transferred to the recording chamber and superfused 
with vehicle control solution. Micropipette solution for whole cell patch clamp recordings was 
composed of: 130 mM potassium aspartate; 5mM MgCl2; 5mM EGTA; 4mM ATP; 10mM HEPES. 
The pH was adjusted to 7.2 with KOH. Micropipette solution was prepared in batches, aliquoted, 
frozen for storage and a fresh aliquot thawed each day. The recording was performed at a temperature 
of 33-35 ºC using a combination of in-line solution pre-heater, chamber heater and feedback 
temperature controller. Temperature was measured using a thermistor probe in the recording 
chamber. Micropipettes for patch clamp recording were made from glass capillary tubing using a P-
97 (Sutter Instruments, Novato, CA) or PC-10 (Narshige, Amityville, NY) micropipette puller. A 
commercial patch clamp amplifier (PC-505B from Warner Instruments, Hamden CT) was used for 
whole cell recordings. Before digitization, current records were low-pass filtered at one-fifth of the 
sampling frequency. 
 
Experimental Procedures. Cells stably expressing hERG were held at -80 mV. Onset and steady 
state inhibition of hERG potassium current due to MMV688533 were measured using a pulse pattern 
with fixed amplitudes (conditioning prepulse +20 mV for 1 s; repolarizing test ramp to -80 mV (-0.5 
V/s) repeated at 5 s intervals). Each recording ended with a final application of a supramaximal 
concentration of the reference substance (E-4031, 500 nM) to assess the contribution of endogenous 
currents. The remaining uninhibited current was subtracted off-line digitally from the data to 
determine the potency of the test substance for hERG inhibition. MMV688533 was tested at 1 μM 
in three cells (n = 3). Inhibitory effects on hERG potassium current amplitude of 17.9, 11.5 and 
12.4% were observed. Based on these results and the solubility limit of the test article in the vehicle, 
additional nominal concentrations (0.3 and 3 μM; Protocol Amendment No. 1) were selected to 
29
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evaluate the concentration-response relationship. One or more test article concentrations were 
applied sequentially (without washout between test substance concentrations) in ascending order, to 
each cell (n ≥ 3). Peak current was measured during the test ramp. A steady state was maintained for 
at least 20 s before applying test article or positive control. Peak current was measured until a new 





Supplementary Figures  
 
Fig. S1. Conditional knockdown (cKD) strategy for PfACG1 and PfEHD. (A) Schematic 
representation of the generation of PfACG1 and PfEHD cKD lines. (B) Western blot-based 
assessment of PfACG1 and PfEHD translational regulation via the TetR-DOZI-RNA aptamer 
module. The expected mass of the PfACG1-2´HA and EHD-2×HA proteins is 55.7 kDa and 66.4 
kDa, respectively. Protein expression was maintained in the presence of aTc, contrasting with 
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Fig. S2. Genetic manipulation strategies for PfACG1 and PfEHD. (A) CRISPR/Cas9 strategy 
to edit SNPs into the endogenous pfacg1 locus. Cas9 was derived from Streptococcus pyogenes 
and codon optimized for P. falciparum; transcription was regulated from a P. falciparum 
calmodulin promoter. The plasmid also contains a hDHFR selectable marker under the PcDT 
promoter and a sequence encoding the guide RNA (gRNA) under a U6 promoter. The pfacg1 
donor has >300bp of homology flanking the mutation of interest (G96V or W286R). (B) attB´attP 
based strategy to integrate pfacg1-eGFP as a transgene into the cg6 locus of NF54attB parasites. 
pfacg1-eGFP and the BSD selectable marker are transcribed from a calmodulin and a PcDT 
promoter, respectively. (C) CRISPR/Cas9 strategy to introduce a 3×HA into the 3’ end of the 
endogenous pfehd locus in NF54attB parasites expressing the pfacg1-eGFP transgene. The 
plasmid also contains a hDHFR selectable marker and a sequence encoding the guide RNA 
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(gRNA), under a PcDT and a U6 promoter, respectively. The donor fragment has two regions of 
pfehd homology flanking the 3×HA tag. attL: attB left junction segment; attR: attB right junction 
segment. BSD: Blasticidin-S deaminase; CAM: Calmodulin; eGFP: enhanced Green Fluorescent 
Protein; gRNA: guide RNA. hDHFR: human dihydrofolate reductase; Hrp2: histidine-rich protein 
2; Int: Mycobacteriophage Bxb1 serine integrase; Neo: Neomycin; pBS: BlueScript plasmid; 
Hsp86: Heat shock protein 86; PcDT: Plasmodium chabaudi dihydrofolate reductase-thymidylate 
synthase; pfacg1: Plasmodium falciparum acylguanidine 1 gene; pfehd: Plasmodium falciparum 
Eps15 homology domain containing gene; SpCoCas9: Streptococcus pyogenes-Plasmodium 


















































































































































































































Fig. S4. Fluorescence microscopy images of fixed and labeled NF543×HA-EHDattB-ACG1-
eGFP parasites. PfACG1 was detected using antibodies specific to eGFP. Costaining used (A) 
anti-PfMDR1 antibodies that label the digestive vacuole membrane (55, 56); (B) anti-plasmepsin 
II antibodies that label the digestive vacuole lumen (57); (C, D) LipidTOX neutral lipid stain that 
stains lipid bodies (58); (E, F) Nile Red that also stains lipid bodies (59); (G, H) anti-ERD2 
antibodies that label the cis-golgi (19); (I, J) anti-PMT that labels phosphoethanolamine N-
methyltransferase present in trans-Golgi structures (20); (K-M) anti-Rab5A, anti-Rab5B and anti-
Rab7 that labels vesicles (22); (N) anti-K13 that labels the ER, vesicles and cytostomes (22); (O) 
anti-coronin antibodies that stain compartments with F-actin (60); (P) MitoTracker Red that labels 
mitochondria; or (Q) anti-ACP antibodies that label the acyl carrier protein present in the  
apicoplast (61). Nuclei were stained with DAPI (blue). Scale bars: 2 µm. 
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Fig. S5. Fluorescence microscopy images of fixed and labeled NF543×HA-EHDattB-ACG1-
eGFP parasites. PfEHD was detected using antibodies specific to HA (magenta). Costaining used 
(A, B) LipidTOX neutral lipid stain; (C, D) anti-PDI that labels the plasmodial protein disulfide 
isomerase that is localized in the ER (62); (E) anti-ERD2; (F) anti-PMT; (G-J) anti-coronin; (K-
0) anti-Rab5A, anti-Rab5B, anti-Rab5C, anti-Rab7 and anti-Rab11A that label vesicles involved 
in trafficking (63, 64); (P) anti-K13; or (Q) anti-ACP antibodies (cyan). Nuclei were stained with 
DAPI (blue). Scale bars: 2 µm. 
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Fig. S6. Fluorescence microscopy images of fixed and labeled NF54pCRISPRTetR-DOZI-
ACG1-2×HA parasites. PfACG1 was detected using antibodies specific to HA (green). 
Costaining used (A) anti-HA stain; (B-C) anti-PfCRT antibodies that label the digestive vacuole 
membrane (65); (D-G) LipidTOX neutral lipid stain; (H-I) anti-PDI; (J-K) anti-ERD2; (L-0) anti-




































Fig. S7. Fluorescence microscopy images of fixed and labeled NF54pCRISPRTetR-DOZI-EHD-
2×HA parasites. PfEHD was detected using antibodies specific to HA (magenta). Costaining used 
(A) anti-HA stain; (B-C) anti-PfCRT; (D) LipidTOX neutral lipid stain; (E-G) anti-PDI; (H) Bip 
antibodies that stain the ER (20); (I-J) anti-coronin; (K) anti-Rab5B. Nuclei were stained with 
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Supplementary Tables  
Table S1A. MMV688533 chemical formula and calculated /experimental properties of malonate salt. 
 
* Technical limit of the Syrius T3 apparatus. tPSA: Topological polar surface area (the sum of the surface 
of all polar atoms, primarily oxygen and nitrogen including hydrogen atoms). Compounds with tPSA >140 
Å suffer from poor cell permeability. pKa: Dissociation constant. LogP: Partition coefficient. LogD: 
Distribution coefficient. LogP is expressed as a log10 of the concentration ratio between non-aqueous 
organic (n-octanol) and aqueous (pH-buffered water). Ideally, compounds should possess a LogP value not 
greater than 5 (otherwise too lipophilic, thereby creating solubility issues). LogD is a distribution 


















C27 H19 F6 N5 O6 (free base: C24 H15 F6 N5 O2)
623.47 g/mol (free base: 519.41 g/mol)
2.4 (base) /5.8 (base)
0
195.03 (free base: 120.43)
7
180°C
All batches synthetized so far are under the same crystalline form 
(anhydrous form)
3.79
3.93 / No value (> 3)*
40
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Table S1B. MMV688533 (malonate salt) solubilization profile against time. 
 
The equilibrium solubility of MMV688533 malonate salt in buffered solutions (room temperature) and physiological relevant 
aqueous buffers (37°C) is pH dependent. Good solubility was observed in acidic conditions and poor solubility under more 
neutral conditions. Because the solubility of malonate salt is difficult to assess in some media due to its conversion into the 
free base form 2 (hydrated form of free base), we determined the concentration of solubilized compound as a function of 
time. LOQ: Limit Of Quantification. Low solubility is < 10 µg/mL; moderate solubility is between 10 µg/mL and 1000 µg/mL; 
high solubility is > 1000 µg/mL. 
 
 MMV688533
Time (hours) 0.25 0.5 1 2 4 24 Medium
Supernatant 
(24h)
pH 1.0 (0.1N HCl) 1750 2480 2870 2670 3770 4780 1.1 1.1 Malonate form1 ≥ 4.7 mg/ml
pH 3.0  2.8 5.4 6.5 7.6 7.2 14.2 2.8 2.9 Malonate form1 ≥ 14 µg/ml
pH 4.5  1.6 2.1 2.72 3 2.8 0.96 4.3 4.3 Malonate form1 ≤ 3 µg/ml
pH 7.4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 7.4 6.5 Base form 2 ≤ 3 µg/ml
Water 1 2 4.3 7.6 10 14.4 N/A 3.1 Malonate form1




Gastric fed state 11 12 14 15 18 27 3.1 3.1 Malonate form1
∼
 27 µg/ml
Fasted state simulated 
intestinal fluid
107 154 15 11 13 20 6.7 4.7 Base form2 ≥ 150 µg/ml
Fed state simulated 
intestinal fluid
3980 3540 1760 1990 2180 150 5 4.8 Base form2 ≥ 3.9 mg/ml
Predicted solubility 
of malonate saltRoom temperature
37°C
X-Ray diffraction 





Table S1C. MMV688533 in vitro IC50 (nM) of culture-adapted lab and field P. falciparum isolates. 
 
MMV688533 potency on chloroquine-sensitive (NF54, 3D7) and chloroquine-resistant (K1, Dd2) parasites, as determined 
from dose-response assays and IC50 analyses, was below 10 nM. This compound showed no cross-resistance with other 
known antimalarials as determined using a diverse panel of  lab-adapted field isolates: HB3, 7G8, TM90C2B, D6, V1/S, 
FCB and Cam3.1. No cross resistance was observed with Dd2 mutant parasites selected for resistance to DDD107498, 
fosmidomycin, MMV390048, GNF156, DSM265 or ELQ300 and which acquired resistance via amino acid substitutions or 
copy number variation (CNV) in eEF2, PFDXR, PFPI4K, PFACRL, PFDHODH and PFCYTB respectively. HCl: Hydrochloric 
acid; *SYBR Green assay; PFEF2: P. falciparum translation elongation factor 2; PFDXR: P. falciparum 1-deoxy-D-xylulose-
5-phosphate reductoisomerase; PFPI4K: P. falciparum phosphatidylinositol 4-kinase; PFCARL: P. falciparum cyclic amine 
resistance locus; PFDHODH: P. falciparum dihydroorotate dehydrogenase; PFCYTB: P. falciparum cytochrome b. 
  
HCl 9.0 8.6 7.3 7.8 2.5 5.5 4.1 4.4 7.1 8.5 - 7.5 8.7 7.2 7.3 - -
Malonate  16 31* - - - - 15 - - - 16 - - 15 - 21 18













Table S1D. MMV688533 activity against P. falciparum liver and gamete stages. 
aLiver stage assays were conducted by the group of Dr. Koen Dechering at TropIQ Health Sciences, 
Nijmegen, The Netherlands. In this assay, the positive control atovaquone yields a mean ± SD IC50 
value of 7 ± 4 nM (66). bInhibition of male and female gametes was measured using the dual 
gamete-formation assay, as described (67). Assays were performed on three independent 
occasions with technical duplicates. The positive control thiostrepton, incubated at 2 µM for 48 
h, yielded 100% and 63% inhibition of male and female gamete formation, respectively. 
Table S1E. MMV688533 in vitro cytotoxicity IC50 (µM) on human 
cell lines and rat hepatocytes. 
MMV688533 showed a selectivity of >1,000 against the three 
designated cell lines tested. There was also no swelling or 
depolarization on rat liver-isolated mitochondria at 62.5 µM. HCl: 
Hydrochloric acid; HL60: Human leukemia cell line; HepG2: 
Human liver carcinoma cells; w/o: without; BSA: Bovine Serum 
Albumin. 
Compound
Liver stage mean 
IC50
Male gamete inhibition 
at 1 µM (mean ± SEM)
Male gamete inhibition 
at 1 µM (mean ± SEM)
MMV688533 4.0 µMa -9.9 ± 2.2%b 2.0 ± 1.2%b
Salt HL60 HepG2 Rat hepatocytes 
HCl 13.1 > 15.6 15.0 (18.0 w/o BSA)
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Table S1F. Summary of efficacy parameters from the P. falciparum-infected human red 
blood cell SCID mouse model study performed in recrudescence mode. 
 
Effective dose 90% (ED90) and area under the curve 90% (AUCED90) are defined as the 
dose in mg/kg and the estimated average daily exposure, respectively, that reduce 
parasitemia by 90%  on day 7 post-infection as compared to vehicle-treated mice. In this 
assay, this level of reduction implies no net parasite growth in blood. AUCPCC and CmaxPCC 
is defined as the minimum average daily exposure (PCC, parasite clearance concentration) 
and maximal blood concentration (Cmax) necessary to achieve maximum parasite clearance 
from peripheral blood. AUCCURE and CmaxCURE are defined as the minimum drug exposure 
and Cmax in blood associated with cure of P. falciparum-infected SCID mice infused with 
human red blood cells. 
 
Non-standard 1-day ED90 2.0 1.9 - 2.1 mg/kg
Non-standard 1-day AUCED90 3,097 2,335 - 4,484 ng.h/ml
Non-standard 1-day AUCPCC 8,046 3,802 - 12,511 ng.h/ml
Non-standard 1-day CmaxPCC 382 231 - 576 ng/ml
Non-standard 1-day AUCCURE > 193,123 - ng.h/ml
Non-standard 1-day CmaxCURE > 5,506 - ng/ml
Units95% Interval of confidenceMeanParameterAssay
44
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Table S1G. Minimal parasiticidal concentration of MMV688533 in the P. falciparum infected 
NSG mouse model. 
 
The minimal parasiticidal concentration (MPC), was determined from the IC90 value of the killing 
curve plotted as a function of the circulating drug concentration and calculated from IC50 and the 
Hill coefficient. The MPC determined from either the IC50 estimate of the final PK/PD run or 
from the median IC50 of its related bootstrap analysis ranged between 14.7 and 20.2 ng/ml. a 
[25,75% quantile] for MPC deduced from [25,75% quantile] for IC50. 
 
  
EC50 origin EC50 (ng/mL) MPC (EC90) (ng/mL)
Final run #79865 (population estimate)  1.63 14.7
Bootstrap analysis: median [25,75% 
quantile] from n= 504 successful runs
2.25 [1.59;3.44]  20.3 [14.3;30.9]a
45
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Table S1H. MMV688533 in vitro metabolic clearances in microsomes 
and hepatocytes from different species. 
 
In vitro metabolic stability studies were performed using liver microsomes 
and cryopreserved hepatocytes of mouse, rat, dog, macaque or human 
origin. Results indicate low metabolic clearances in all species. CLint: in 
vivo intrinsic clearance. Low liver microsome CLint values are < 10 
µL/min/mg, moderate values are between 10 and 50 µL/min/mg, and high 
values are > 50 µL/min/mg. Low hepatocyte CLint values are < 4 mL/h/106 
cells; moderate values are between 4 and 20 mL/h/106 cells; and high 
















Table S1I. MMV688533 inhibition of cytochromes P450 (CYP). 
 
Data shown above were generated with purified CYP enzymes. When tested in vitro with 
human liver microsomes, MMV688533 did not inhibit CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A at concentrations up to 10 μM. 
 
  
CYP1A2 Phenacetin no inhibition
CYP2B6 Bupropion 56.4 Mixed 12.6
CYP2C8 Amodiaquine 1.6 Mixed 0.8
CYP2C9 Diclofenac 3.3 Mixed 2.4
CYP2C19 S-Mephenytoin 13.7 Mixed 9.0
CYP2D6 Dextromethorphan 10.6 Competitive 4.0
CYP3A4/5 Midazolam 8.2 Mixed 15.3




IC50 (µM)Selective substrate CYP enzyme
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Table S1J. MMV688533 pharmacokinetic parameters in male Swiss mice and male Sprague Dawley rats after intravenous 
and oral route administration. 
 
MMV688533 was administered by oral gavage (po, with compound suspended in methylcellulose/Tween 80 0.6%/0.5% in 
water) and by IV route as a solution using PEG200/ solutol/ G5% (20/5/75; w/w/v) to male Swiss mice (PKS10191-VA) and 
male Sprague Dawley rats respectively. Compound concentrations were determined by LC-MS/MS, with a Limit of 
Quantification (LOQ) of 2 ng/mL for plasma and 5 ng/mL for blood. (-) below the LOQ. In both species, the clearance (CL) 
is equivalent to the relatively low value of 0.005 µL/min/mg. In rodents, a T1/2 value (po) > 8h is considered as a long half-
life when translated into humans. F (%), percent bioavailability. B/P, blood to plasma ratio. ND, not done. 
 
Intravenous 3 Plasma 6.14 10.3 0.29 1.36 3.2 - - -
Per os 3 Blood 0.86 11.7 - - 4 8 - -
Per os 10 Plasma 2.24 33 - - - 4 96 -
Per os 10 Blood 2.21 30 - - 16 8 - 1.2
Per os 30 Blood 8.13 152 ND ND 26 4 ND ND
Intravenous 3 Blood 5.65 9.5 0.30 2.09 7.5 - -
Per os 10 Blood 1.14 22.8 - - 9.6 4 71
Male Swiss mice
Male Sprague Dawley rats












Table S1K. MMV688533 pharmacokinetic parameters in male Sprague Dawley rats after oral administration. 
 
MMV688533 malonate salt was administered at 30 and 300 mg/kg by oral gavage (methylcellulose/Tween 80 0.6%/0.5% in 
water) to male Sprague Dawley rats. Concentrations were determined using LC-MS/MS, with a limit of quantification of 25 ng/ml 
for blood and 125 ng/g for tissues. At the 30 mg/kg dose level, the highest concentrations were reached at 6 h post-dosing and the 
exposures increased roughly proportionally with dose between 30 and 300 mg/kg for AUC exposure while Cmax increased sub-
proportionally with dose. The quantitative tissue distribution was also evaluated in brain, liver, lung, heart and kidney at the 30 
mg/kg dose level after oral administration. Broad distribution of MMV688533 was observed with tissue/blood concentration 
ratios above 1 in all tissues except the brain. The Tmax ranged mostly between 4 and 24 hours. The highest levels (tissue/blood 
concentration ratio = 55) were observed in lung > liver > kidney > heart > brain. Penetration into brain was significantly lower 
compared to penetration into other tissues. *Tissue:blood AUC ratio. 
 
Malonate Per os 30 Blood 6.0 6 310 310 16 -
Malonate Per os 300 Blood 30 48 2800 2800 38 9.1
Malonate Per os 30 Brain 3.2 4 140 160 24 0.5*
Malonate Per os 30 Liver 246 6 11000 11000 21 35*
Malonate Per os 30 Heart 81 6 3200 3200 19 10*
Malonate Per os 30 Kidney 182 4 7500 7500 16 24*















Table S1L. MMV688533 blood toxicokinetic parameters in male and female 
Sprague Dawley rats. 
 
MMV688533 maximal blood concentrations (Cmax) were reached in females at 24 h post-dosing (last sampling time) and in males at 8 
h post-dosing on Day 1 at 100 mg/kg. In females, MMV688533 Day 4 dose proportionality (Cmax and AUC0-24) over the 25-50 mg/kg/day 
dose range increased slightly supra-proportionally and were similar to the 50-100 mg/kg/day dose range. A 2-fold increase in dose (50 
mg/kg/day vs 25 mg/kg/day) led to a 3.1-fold increase in Cmax and a 3.4–fold increase in AUC0-24 and a further 2-fold increase in dose 
(100 mg/kg/day vs 50 mg/kg/day) led to a 1.1-fold increase in Cmax and a 1.1–fold increase in AUC0-24. In males, a slightly sub-
proportional increase was observed. MMV688533 exposures increased in proportion over the 50-100 mg/kg/day dose range. A 2-fold 
increase in dose (50 mg/kg/day vs 25 mg/kg/day) led to a 3.0-fold increase in Cmax and a 3.3–fold increase in AUC0-24. A further 2-fold 
increase in dose (100 mg/kg/day vs 50 mg/kg/day) yielded a 2.3-fold increase in Cmax and a 2.2–fold increase in AUC0-24.  At 100 
mg/kg/day, MMV688533 mean accumulation ratios (D4/D1) in blood were 1.8 for both AUC0-24 and Cmax in females and 2.5 AUC0-24 
and 2.4 Cmax in males. Based on MMV688533 Cmax and AUC0-24 in blood, no gender effect was observed on Day 1. On Day 4, exposure 
in females was slightly higher with a female to male ratio ranging from 1.7 to 1.8 after dosing with 25 mg/kg/day or 50 mg/kg/day. No 
gender effect was observed at 100 mg/kg/day on Day 4, with a female to male ratio of 0.86 to 0.88. -, not determined. Two rats (one 
male and one female) were used per dose. 
Day 1 Day 4 Day 1 Day 4 Day 1 Day 4
Male 25 Blood - 3.0 - - - 57.6
Male 50 Blood - 8.9 - - - 188
Male 100 Blood 8.6 20.4 8 24 163 413
Female 25 Blood - 5.2 - - - 99.4
Female 50 Blood - 16.0 - - - 335
Female 100 Blood 10.1 17.9 24 24 195 355
Sex





Table S1M. MMV688533 mean biliary and urinary 
excretion parameters in male Sprague Dawley rats. 
 
Biliary and urinary excretion was evaluated over 24 h 
after intravenous administration of 10 mg/kg 
MMV688533 as a solution of 40% Captisol in water to 
dual cannulated (bile duct and duodenum) male Sprague 
Dawley rats. An exploratory LC-MS/MS method with a 
limit of quantification of 1 ng/ml was used to quantify 
urine and bile samples. Data are shown as mean ± SD 
(CV%), from three rats. Low biliary and urine excretions 
were observed with around 2% of the administered dose 





0-4 1.36 ± 0.28 (12) -
0-8 1.48 ± 0.28 (19) -
0-24 2.05 ± 0.38 (18) 2.22 ± 1.13 (51)
 Excreted drug cumulated over 24 
hours (% of administered dose)
51
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Table S1N. MMV688533 mean pharmacokinetic parameters in female Beagle dogs after intravenous 
injection. 
 
MMV688533 was administered to 3 female Beagle dogs via intravenous route as a solution using 
PEG400/Ethanol/Solutol HS15/G5% (20/5/5/75) pH 3.0. Compound concentration was determined using 
LC-MS/MS. The limit of quantification was 5 ng/ml for blood. CL is equivalent to 0.011 µL/min/mg and 
is indicative of low clearance. In humans, compounds with a volume of distribution (Vss) < 4 L are 
expected to be found exclusively in plasma. When Vss is > 40 L, compounds are distributed in all tissues 


















Intravenous 2 Blood 1.8 19.8 > 30% 0.07 4.74 50.7
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Table S1O. Mean blood pharmacokinetic parameters of MMV688533 and its metabolite RA14677213 following a single oral 
administration as capsule or oral solution to pentagastrin-induced male Beagle dogs. 
 
The pharmacokinetics of MMV688533 and its metabolite RA14677213 were investigated in blood after a single 0.5 mg/kg dose 
that was orally administered to male Beagle pentagastrin-induced dogs. The solution formulation was at 0.25 mg/mL in 
PEG400/Ethanol/Solutol/G5% (20/5/7.5/67.5). The capsule formulation [MMV688533 /microcrystalline 
cellulose/croscarmellose sodium (5/91.67/3.33)] was followed by 50 ml water. 30 minutes before oral administration, the dogs 
were treated with pentagastrin (intra-muscular injection, 6 μg/kg, 0.25 mL/kg). The gastric pH was measured before dosing and 
was found to be < 3.0. MMV688533 and RA14677213 were quantified using LC-MS/MS with limits of quantification of 0.83 
ng/ml and 1.0 ng/ml, respectively. Maximal MMV688533 blood concentrations were observed between 2-24 h for the capsule 
and between 2-4 h for the solution. MV688533 exposure observed after oral administration as capsule was around 25% lower 
compared to exposure observed after oral administration as solution. For RA14677213, the maximal blood concentrations were 
observed between 2-4 h for the capsule and between 4-6 h for the solution. Similar pharmacokinetic profiles were observed 
between MMV688533 and its metabolite. The elimination half-life for both capsule and solution formulations was ~40 h for 
MMV688533 and ~50 h for its metabolite. On average, RA14677213 represented around 22% of parent exposure for both 
formulations. 
 









(µg.h/mL) Tlast (h) T1/2 (h)
MMV688533 Capsule 89.7 10.7 (2-24) 1.55 4.58 4.85 168 41
MMV688533 Solution 99.6 2.67 (2-4) 1.99 6.09 6.49 168 42.8
RA14677213 Capsule 19.9 3.33 (2-4) 0.36 1.13 1.24 168 51.5
RA14677213 Solution 22 5.33 (4-6) 0.405 1.38 1.54 168 51.6
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Table S1P. MMV688533 predicted human 
parameters. 
 
Mahmood rules and Fixed exponent 
method of allometric scaling of clearance 
from animal data predicted a low to a very 
low MMV688533 clearance (3.6 and 1.4 
L/h (< 5%) of hepatic blood flow) in 
humans. This corresponded to a predicted 
half-life of 103 and 277 h respectively. The 
volume of distribution relying on allometry 
method with an exponent of 1 was 





(L/h) T1/2 (h) Vdss (L)
Low: 3.6 103 5.0
Very low: 1.4 277 5.0
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Table S1Q. MMV688533 in silico prediction of genotoxicity/organ toxicity. 
 
Knowledge-based approach using the software Derek and QSAR based (Leadscope) 
were used to predict in silico genotoxicity, hepatotoxicity, nephrotoxicity, cardiotoxicity 
and phototoxicity. (* moderate in vitro and low in vivo). 
 
  
Toxicity Derek Leadscope Internal toxicity results
Mutagenicity No alert No alert No alert
Clastogenicity No alert No alert No alert
Hepatotoxicty No alert Not relevant To be monitored
Nephrotoxicity No alert Not applicable To be monitored
Cardiac toxicity No alert Not applicable To be monitored
Phototoxicity No alert moderate/low risks* No alert
55
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Table S1R. MMV688533 off-target activities. 
 
Off target potential pharmacological activities of MMV688533 were assessed in a full CEREP 
profile on 19 enzymes (uptake assays), 88 receptors (binding assays), ion channels and amine 
transporters at 1 µM inhibition activity. The criterion for dose-response determination was 
"greater than 60% inhibition of activity or displacement of the labeled ligand". MMV688533 
was found inactive at 1 µM on a panel of 315 kinases. Interactions of MMV688533 with 
receptors – although at very high concentrations – carry an alert for central nervous system 
and cardiovascular effects. These alerts have not been confirmed when assessed through in 




BZD (peripheral) (antagonist radioligand) 0.9
Ca2+ channel (L, dihydropyridine site) (antagonist radioligand) 1.1
Cl- channel (GABA-gated) (antagonist radioligand) 4.3
Dopamine transporter (h) (antagonist radioligand) 9.4
Sigma (non-selective (h) (agonist radioligand) 4.8
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Table S1S. MMV688533 in vitro activity in µM on 
different cardiac ion channels. 
 
No cardiotoxicity alert was identified with MMV688533 
from all the evaluated in vitro endpoints. 
 
Table S1T. MMV688533 non-compartmental analysis of exposure 
in male Sprague Dawley rats. 
 
The steady-state AUC0-24h and cumulated AUC in 2-week toxicity 
studies were calculated using a non-compartmental analysis. Five 
animals per dose and sex were used to determine the concentration of 




Potassium channel (hERG) 4.6
Sodium channel (Nav1.5) 14
Calcium channel (Cav1.1) 2.1
Dose 
(mg/kg)








Table S1U. MMV688533 cumulated exposure over 14 days of treatment in Beagle dogs.  
 
Cumulated AUC was calculated from 2-week toxicity studies using a population pharmacokinetic model. 
 
Table S1V. Calculation of MMV688533 safety margin based on cumulative AUC over 14 
days at the NOAEL dose in rats and dogs. 
 
For rats the therapeutic index based on the cumulative AUC over 14 days at the NOAEL (No Observed Adverse Effect Level) dose of 
12.5 mg/kg in rats, as compared with the AUC from an estimated single oral dose of 30 mg in humans, was estimated to be > 20. For 
dogs the therapeutic index calculated based on the cumulative AUC over 14 days at the NOAEL dose of 1 mg/kg in dogs, compared 
with the AUC from an estimated single oral dose of 30 mg in humans, was estimated to be 14. Whole blood exposure in humans was 
predicted based on compound efficacy in the Pf SCID mouse model and the calculated in vitro PRR of 3.0.  






over 15 days 
(mg/kg)
mean mean Male & Female
0.5 once daily 7.5 30,000 27,400 28,700 52,000 32,300 42,200 35,400 (27,400-52,000)
1.0 (QD) 15 76,600 87,700 82,200 67,400 86,000 76,700 79,400 (67,400-87,700)
2.0
once every 2 
days (Q2D) 
14 73,300 76,200 74,800 41,100 69,100 55,100 64,900 (41,100-76,200)
FemaleMale






Exposure (AUC0-inf, µg.h/mL) 




Rat 12.5 747 5.7 >20
Dog 1.0 79 5.7 13.8
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Table S2. Asexual blood stage IC50 data in nM of MMV688533-resistant parasite lines against common antimalarials. 
  
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates).  ed., gene edited. sel., selected under 
















KAE609 0.7 0.1 3 0.7 0.0 3 0.6 0.02 3 0.7 0.04 3
Dihydroartemisinin 0.8 0.2 3 0.7 0.1 3 0.9 0.1 3 0.7 0.04 3
Lumefantrine 1.5 0.3 3 1.2 0.04 3 1.2 0.02 3 0.9 0.04 3
Chloroquine 5.5 1.0 3 6.2 0.1 3 8.3 1.1 3 9.2 1.5 3
Mefloquine 10.6 0.4 3 9.3 0.1 3 11.0 0.5 3 6.1 0.7 3
Ferroquine 6.5 1.3 3 8.1 0.4 3 11.5 1.9 3 12.1 2.6 3
Piperaquine 14.8 2.6 3 12.6 1.0 3 17.8 1.4 3 15.4 2.1 3
Quinine 24.5 3.7 3 22.2 1.3 3 25.2 2.6 3 15.4 0.8 3
md-amodiaquine 24.1 2.4 3 26.5 1.5 3 30.9 2.2 3 31.2 7.4 3
GNF179 45.7 9.1 3 42.4 7.1 3 55.0 11.2 3 35.1 7.4 3
Fosmidomycin 359 22 3 401 38 3 331 37 3 248 9.7 3
3D7-A10 wild type sel. ed. 533-CL1EHD-D218Yed. 3D7 ACG1W286Red. 3D7 ACG1G98V
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Table S3: Protein functional pathway relationships.     
 




Conserved Plasmodium  protein (PfACG1) PF3D7_0910300 Q8I349_PLAF7 - - - -
EH domain-containing protein (PfEHD) PF3D7_0304200 Q9NLB8_PLAF7 vesicle transport heterocyclic compound -
Conserved Plasmodium  protein PF3D7_0510100 Q8I403_PLAF7 - - heterocyclic compound RNA binding
RNA pseudouridylate synthase, putative PF3D7_0511500 Q8I3Z1_PLAF7 - - heterocyclic compound RNA binding
ATP synthase (C/AC39) subunit, putative PF3D7_1464700 Q8IKJ0_PLAF7 - transport heterocyclic compound -
GO_function2Gene product Gene ID Protein ID GO_component GO_process GO_function1
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